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(Under the direction of Pam Silberman) 
 
The uninterrupted availability of health products is essential for the provision of 
HIV/AIDS services. A 2015 assessment of public health supply chain systems in Nigeria 
supporting HIV/AIDS services revealed that some vital HIV/AIDS products were unavailable in 
about 9%–16% of health facilities visited. This implied >10% of the health facilities visited did 
not have all the life-saving HIV/AIDS commodities needed to provide needed clinical services. 
Health commodity unavailability interrupts health service delivery, negatively affects the quality 
of services and adversely affects patient adherence to treatment. This suggests a need for 
changes in the HIV/AIDS supply chain management (SCM) system. 
The aim of this study was to explore structural and systemic improvements needed to 
promote effective and efficient public-sector pharmaceutical SCM system for HIV/AIDS service 
delivery in Nigeria through; (I) identification of current gaps in the pharmaceutical SCM system, 
(II) identification of potential solutions to address the gaps, (III) exploring effective solutions in 
Nigeria and other places, and (IV) identification of policy improvements for the pharmaceutical 
SCM system. The study was conducted using sequential mixed-method design of surveys and 




The results identified poor logistics data management and use, poor information 
dissemination for decision-making, limited leadership and funding, poor performance 
management and limited human resources capacity to support SCM services that disrupts 
HIV/AIDS service delivery. Some of the solutions to address these gaps include: use of 
electronic systems for logistics data management to enhance decision-making, more 
widespread dissemination of information on changes in clinical guidelines and the SCM system, 
improvements in government leadership and funding, establishment of an accountability 
structure, improved performance management of private sector contracted to support the supply 
chain system, and improved human resource management. In addition, the study identified the 
need to set policies on minimum remaining shelf-life requirements for donated health products, 
minimum levels of government funding to support the supply chain system, and an 
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The 2015 assessment of public health supply chain systems in Nigeria supporting 
HIV/AIDS service delivery revealed that some vital HIV/AIDS products were unavailable in 
about 9%–16% of health facilities visited (Ajulo et al., 2015). This implied >10% of the health 
facilities visited did not have all the life-saving HIV/AIDS commodities needed to provide needed 
clinical services. With about 748,000 persons on antiretroviral therapy (ART) in Nigeria from 
6,500 health facilities (NACA, 2015), the unavailability of these products creates significant 
access barriers to life-sustaining treatment for many patients with HIV/AIDS. Health commodity 
unavailability interrupts health service delivery, negatively affects the quality of services, and 
adversely affects patient adherence to treatment. The inability to provide life-saving medicines 
can lead to loss of lives, especially in emergency health service delivery situations (MSH, 2012).  
There have been several studies on the problem of stock-outs (i.e. unavailability) of 
health products for HIV/AIDS and for maternal, infant and child health services. For example, in 
the Kinondoni district of Tanzania, Mori and Amani (2014) conducted a cross-sectional study on 
antiretroviral drugs (ARVs) availability in 20 health facilities. The study documented lack of 
some vital ARVs in 16 out of the 20 health facilities. This resulted in change of treatment 
regimen as a coping strategy (Mori & Amani, 2014). This abrupt change in treatment regimen 
for no therapeutic or pharmacological reasons but product stock-out negatively affects long-term 
HIV treatment planning, may affect drug efficacy, and could result in poor treatment outcomes. 
Conversely, studies have shown that availability of needed health products can improve health 




Misoprostol (life-saving medicines) improved maternal, newborn and child health outcomes in 
Sokoto State, Nigeria. The United Nations’ Commission on life-saving commodities for women 
and children also highlighted the cardinal role health products play in health service delivery 
(UN, 2012). Without health products, the health workers will not be able to deliver complete 
package of clinical services to the patients. 
Several definitions of Supply Chain Management (SCM) exist in literature. This study 
adopts the Council for Supply Chain Management Professionals (CSCMP) definition, which is, 
“the planning and management activities that ensure the availability of needed products from 
the manufacturers to end users” (CSCMP, 2011). These include coordination and management 
of human resources and materials from sourcing to last mile delivery (CSCMP, 2011). In the 
health sector, effective and efficient pharmaceutical SCM ensures that pharmaceutical products 
are available at the health facilities where and when they are needed at the most efficient cost 
to the program. Thus, the success of health programs is dependent on optimally functioning 
supply chain system. (Appendix 1 includes a definition of key terms). Without the products—
such as necessary medicines—healthcare workers will not have the right medications to deliver 
services to the clients resulting in service disruption (USAID│DELIVER PROJECT, 2009).  
Over the last ten years, the public-sector pharmaceutical SCM system for HIV/AIDS in 
Nigeria has made several changes to the structures and processes aimed at improving the 
efficiency and effectiveness of the system. Some of these modifications are donor-driven and 
result in the creation of private sector-managed parallel pharmaceutical systems, different from 
the existing government HIV/AIDS pharmaceutical system (Chima & Homedes, 2015). These 
parallel systems often develop when there is a breakdown in the public-sector SCM system, 
leading to an emergency need to provide life-saving medications at clinics (Windisch, Waiswa, 
Neuhann, Scheibe, & Savigny, 2011).  There are no standardized policies to update or modify 
the SCM system in the public nor private sector-managed parallel systems, leaving the 




these modifications are often made without first assessing the capacity of the current system, to 
support required service delivery. Hence, they often negatively affect system performance. For 
instance, there is a delay in the time it takes to supply HIV/AIDS products from the warehouses 
to health facilities as result of SCM modifications. In the past, based on my experience in the 
SCM system, such requests for supply could be made and within two weeks of the requests, 
supplies would be completed. However, with recent changes in the supply chain system, it has 
increased to between three to five weeks. This came about as result of the request by the 
donors to increase the number of pharmaceutical products supplied to health facilities to include 
pharmaceuticals for tuberculosis treatment. In addition, the number of health facilities that 
receive pharmaceutical products from the SCM system increased astronomically from less than 
1,000 to over 6,000 health facilities within 2 years. The delay caused by the new requirements 
and additional clinics results in the lack of essential HIV/AIDS medications at service delivery 
points when needed. This lack of structural processes to accommodate modifications to the 
SCM is a major challenge. While expansion of clinics improves access to health services, when 
not well planned, the scale-up often disrupts SCM system. 
Currently, discussions are ongoing to modify the inventory management protocols by 
revising the distribution frequency of supplies to health facilities from bi-monthly (every 2 
months) to quarterly (every 3 months). This will require health facilities to increase the 
stockholding capacity from four months of stock to five or six months of stock (i.e. how long 
products supplied to the clinics will last at the current rate of utilization). This modification was 
proposed to address recommended changes in the HIV/AIDS treatment protocol from the 2016 
World Health Organization Consolidated Guidelines for HIV/AIDS service delivery that was 
adapted by the Government of Nigeria (FMOH, 2016). While these discussions are intended to 
support service delivery, there are no procedures that specify how to implement the changes. In 
addition, Nigeria does not have specific implementation procedures to avert service disruptions 




al., 2011; Windisch et al., 2011). With the lack of documented procedures for pharmaceutical 
SCM modifications, new organizations that come into the system do not have guidelines to 
follow. In addition to lack of processes to follow when making system modifications, several 
other factors affect product availability in health facilities. These include inaccurate data needed 
for decision-making (Hasselback et al., 2014), inadequate skilled human resources (Brown & 
Gilbert, 2014), and poor warehousing and distribution infrastructures (Daff, Seck, Belkhayat, & 
Sutton, 2014; Yadav, 2015). The study will explore these in the Nigeria context for effective and 
efficient pharmaceutical SCM for HIV/AIDS. 
An effective and efficient pharmaceutical SCM ensures that the “six rights” of the SCM 
are always maintained to promote uninterrupted health product availability (USAID I DELIVER, 
2011). These “six rights” are the hallmark of a well-designed, effective, and efficient SCM 
system within a health program. These include the right products (based on policy 
specification), that need to be available in the right quantities (based on guidelines on inventory 
holding capacity of the service delivery point), at the right time (considering the patients’ clinical 
appointments), in the right place (the selected location for service delivery), at the right condition 
(not expired or damaged) and at the right cost for the patients (for efficient management of 
resources both for the SCM and the patients). These “rights” denote the primary purpose of 
pharmaceutical SCM system to provide health services to the clients (USAID│DELIVER 
PROJECT, 2011). The “six rights” are essential in quality monitoring of SCM to identify 
inadequacies in the systems and/or processes that support uninterrupted supply of health 
products.  
The Nigerian public-sector pharmaceutical SCM system has been subject of at least 
three studies in the last five years. A study of the HIV/AIDS pharmaceutical system identified 
challenges on lack of standardized logistics data collection system and management within the 
program as major bottleneck to SCM system harmonization (Agudelo et al., 2012). The authors 




transmission of the data from the clinics to the federal level had made long-term planning for 
commodity needs difficult. Another study, the Nigeria National Supply Chain Assessment 
highlighted the weaknesses of the fragmented pharmaceutical SCM systems (Ajulo et al., 
2015). The authors noted that Nigeria has parallel public-sector pharmaceutical SCM systems 
that are operated independently by each health programs (e.g. HIV/AIDS, Malaria, Family 
Planning, Tuberculosis, and Vaccine). Some of the problems noted for the HIV/AIDS 
pharmaceutical SCM included a lack of standardized logistics data and data collection tools 
across the programs, unreliable data to guide decision-making on pharmaceutical product 
needs, and the lack of standardized inventory management practices. The authors also noted 
inadequate funding to procure needed pharmaceutical products, and a lack of leadership at the 
governmental level needed to coordinate procurement across programs (Ajulo et al., 2015). 
Earlier assessments of the pharmaceutical SCM for HIV/AIDS and the Family Planning program 
SCM also noted similar findings on fragmented pharmaceutical SCM systems (Agudelo et al., 
2012; Bock, Tien, Igharo, Adedeji, & Agudelo, 2011).  
The 2015 assessment recommended development of a coordination framework for the 
pharmaceutical SCM processes that will leverage on the strengths of the various systems. 
Specific recommendations include the establishment of a robust system for procurement order 
tracking at the national level, the need for capacity-building of government institutions on 
quantification, and harmonization of the inventory control parameters and reporting systems 
(Ajulo et al., 2015). This was similar to the recommendations of the 2012 assessment of the 
HIV/AIDS program but with emphasis on logistics data management systems (Agudelo et al., 
2012).  
The government has taken some steps to implement the 2015 recommendations; for 
example, the Government had set up a coordination framework for the HIV/AIDS commodities 
procurement (across the multiple donors). This coordination framework helped to minimize 




there is not a robust procurement tracking system that provides real-time status of all 
procurements and resources expended. This is due to the sensitive (and often confidential) 
nature of procurement information within the government systems, especially as related to 
costs. Government has also taken steps to build capacity of staff, through the support of donors, 
on quantification of HIV/AIDS products. However, the increase in the attrition of trained staff had 
limited the impact of these capacity-building efforts. Furthermore, Government is leading an 
ongoing discussion on changing the inventory control system for HIV/AIDS program to maintain 
a harmonized SCM system across the country. A decision has not been made because of the 
various programmatic considerations (e.g. clinical adherence of patients on medications, 
warehouse capacity in the clinics to accommodate large supplies, shelf life of the drugs etc.). 
This decision will impact on whether HIV positive patients on antiretroviral drugs will continue to 
receive two months of antiretroviral drugs prescription during each clinic visit, as is the current 
practice, or will receive medications that will last up to six months. The harmonization of the 
inventory control system, as part of the ongoing discussion, will be used to address the lack of 
standardization in logistics data collection tools and systems within the HIV/AIDS program.   
Finally, the recommendations from the 2012 HIV/AIDS SCM study partly informed the 
creation of an electronic data management system that would have supported the HIV/AIDS 
program. Unfortunately, the support for this system was aborted in 2014 with the withdrawal of 
funding by the donor supporting the program as result of change in priorities. A new discussion 
across multiple donors is currently at the initial stages due to the ongoing problems in managing 
logistics data across 5,000 clinics offering HIV/AIDS services in Nigeria. These discussions will 
inform the development of a strategy for an electronic logistic data collection and management 
system in 2018 or 2019.  
Public health sector leaders and managers must understand the structural and systemic 
gaps that impede the “six rights” in pharmaceutical SCM. This will enable them develop 




stakeholders. They also need this knowledge to ensure system improvement and performance 
management, and to develop proper accountability mechanisms. Currently, State governments 
in Nigeria are setting up logistics management coordinating unit (LMCU) to oversee the 
pharmaceutical supply chain at the health facilities. In some states, efforts are ongoing within 
the last 12 months to establish the LMCU structures at the local government areas (i.e. 
districts/counties). These units will need skilled human resources. A national coordinating body, 
the National Product Supply Chain Management Program (NPSCMP) will supervise activities of 
the LMCU. Figure (1) provides a summary of the structures and their roles. These accountability 
structures established by the Government are responsible for coordinating and monitoring 
HIV/AIDS pharmaceutical SCM. However, the role of these institutions in various states are still 
evolving while their ability to coordinate pharmaceutical SCM systems is limited by lack of 
human and financial resources. Understanding role of LMCU and NPSCMP in giving support to 
the pharmaceutical SCM system will aid in the development of effective and efficient solutions to 
identified gaps. Nigeria started a National AIDS Indicator and Impact Survey (NAIIS) in June 
2018. This study uses a population-based survey that will provide insight on the estimated 
number of persons living with HIV and their geographic location. The survey findings are 
expected to guide HIV/AIDS service delivery and resource deployment plan, including SCM 
services, based on disease burden from 2019. It is my hope that findings from this study will 
inform policy development and implementation plans that aligns with results of NAIIS to create 








Research Question and Aims 
 
The aim of this research will be to make policy recommendations and develop a plan to 
inform changes in management structures, systems and processes needed to promote effective 
and efficient pharmaceutical supply chain management for HIV/AIDS service delivery in Nigeria. 
To achieve the aim of the research, I will explore this research question:  
What structural and systemic improvements are required to promote effective and 
efficient public-sector pharmaceutical supply chain management for HIV/AIDS service delivery 
in Nigeria?  
Additional sub-questions will be: 
Develop national supply chain coordination framework
Coordinate all health supply chain activities in Nigeria
Coordinate collation and dissemination of health supply chain data
Support establishment of state LMCU and review their performance
Lead Monitoring and Supportive visits to state LMCU
Lead capacity building of health workers on supply chain
Collect, collate and disseminate health supply chain data at states
Coordinate development of commodity distribution plan
Monitor supply chain activities at Local government and clinics
Report health supply chain activities to the Federal government
Logistics Management Coordinating Units (Local Government)
Facilitate data collection from clinics and submission to the states
Providing monitoring and supervison to assigned clinics
Data Flow
Feedback Flow
Provide services to clients
Record health supply chain and service data
Submit health supply chain data to LMCU
Nigeria Government Health Supply Chain Management Structure
Clinics




   
   




   
   
   







National Product Supply Chain Management Programme (Federal Government)




 Aim 1: What are the gaps in the current pharmaceutical SCM system for 
HIV/AIDS service delivery that have created barriers to achieving the six “rights” 
of pharmaceutical SCM?  
Method: Surveys of health workers, program managers, and donors in the SCM. 
 Aim 2: What are potential solutions to address these gaps in the current 
pharmaceutical SCM system for HIV service delivery and promote long-term 
effectiveness and efficiency?  
Method: Surveys and Key Informant Interviews 
 Aim 3: Are there other models of effective SCM systems that could be adopted 
for an effective and efficient pharmaceutical SCM system for HIV/AIDS? (In 
Nigeria, elsewhere?)  
Method: Literature Review and Key Informant Interviews 
 Aim 4: What policy change(s) will promote an effective and efficient 
pharmaceutical SCM system for HIV/AIDS service delivery in Nigeria?  
Method: Key Informant Interviews. 
 
Benefits and Significance of the Study  
 
This study will identify improvements in structures and systems needed to create 
effective and efficient pharmaceutical SCM system for HIV/AIDS that meets public health goals 
of the country. The study will be used to make specific policy recommendations to improve the 
pharmaceutical SCM system. Further, as the final product, the study will be used to develop a 
plan for change that highlights some of the actions that can aid to solve some of the structural 




Over the last decade, I have been working with Non-Governmental Organizations 
(NGOs) in helping to lead the national HIV/AIDS pharmaceutical SCM system. Under the 
Supply Chain Management System (SCMS) Project, I supported the government in estimating 
national HIV/AIDS product requirement, and in designing, implementing, and assessing the 
pharmaceutical SCM system. These are based on the United States Government (USG) 
guidance for the U.S. President’s Emergency Plan for AIDS Relief (PEFPAR) program. I am 
also involved in developing pharmaceutical SCM standard operating procedures for HIV/AIDS 
program, capacity development for Government counterparts, and formulation of national 
pharmaceutical SCM policy for Nigeria. These experiences had given me insight into the 
different components of the system. My knowledge of the system informed my research 
method. It will also guide how I will channel the findings from the research to make desired 
system changes. I will have the opportunity to promote the implementation of some of these 
systemic changes. This I hope will happen as I am still involved in SCM leadership role through 
the USAID Global Health Supply Chain program - Procurement and Supply Management 
(GHSC-PSM) project in Nigeria. However, for the purpose of the research, I tried to ensure that 
my personal bias did not influence the data collection, analysis, and interpretation. I did this by 
limiting eye contact during the interview and following a rigorous codebook development using 
the conceptual framework. A second coder for consistency further reviewed this codebook and 






CHAPTER 2: LITERATURE REVIEW 
Pharmaceutical SCM is often discussed in fields outside of public health, including 
business management and engineering. I searched several databases to find pharmaceutical 
SCM published works in the mainstream journals for public health audience: PubMed Central, 
Scopus, Global Health, and Embase. I also searched BioMed Central because articles in 
PubMed Central linked to this database. Based on knowledge of the study area, I also 
conducted hand searches in grey literatures in the John Snow, Inc. (JSI) USAID│DELIVER 
PROJECT, Management Sciences for Health (MSH) websites and Google Scholar and regular 
Google search engines. Finally, I searched available Nigeria policy documents on HIV/AIDS 
service delivery and pharmaceutical SCM for relevance to the research question.   
Search Strategy  
The search used the following key terms; “procurement and supply management”, 
“pharmaceutical supply chain management”, “supply chain”, “leadership”, “health commodities”, 
“governance”, “HIV service delivery”, “sustainability”, “effectiveness” and “Nigeria”. These 
concepts and terms were used in different combinations in the search engines to assist in 
filtering. The search focused only on English language articles from 2005 as this was period of 
significant changes in the Nigeria pharmaceutical supply chain space. In PubMed Central, I 
used relevance to arrange citations. The search covered both titles and content of the key 
words or their synonyms in the abstract. In Scopus, I filtered the search by articles and 
medicines to limit the number of citation hits reviewed as this database covered articles in 




Antiretroviral drug as sub-filter to bring out citations that were relevant. In BioMed Central, there 
was no filtering strategy; hence, I used the search terms to pick published articles some of 
which were also in PubMed Central. Furthermore, I searched grey literature on the 
USAID│DELIVER PROJECT and MSH websites that are known to be involved in 
pharmaceutical SCM with focus on human resources management in health and leadership. 
This aided in generating reports, studies, and practical field lessons on implementation of 
pharmaceutical SCM. Adapting from Liberati et al. (2009) below is the PRISMA diagram on the 
literature review process and outcome (Figure 2). 
Figure 2: Systematic Literature Review Strategy 
PubMed Central 
(n= 3,279)






Embase               
(n= 659)
Hand Search                                              
(n=15)
Total with duplicates(n=7,968).           
Total without duplicates (n=4,215)
Total screen for relevant title 
(n=4,215)
Irrevelant titles (n=4,165)
Total reviewed for abstract (n=50)
Irrevelant abstracts (n=8)
Full articles reviewed (n=42)
Exclusion Criteria: i) Lack of clarity on method (n=5) (ii) 
conference presentation without details (n=8) (iii) SCM 
not main theme (n=2) (iv) Not in developing country 
(N=4) (v) not focused on service delivery  (n=1)





Inclusions and Exclusion Criteria   
I limited my search to publications that had any of the key search terms in title or 
abstract. I excluded articles that were not directly related to SCM of health products and health 
services delivery. Also, I excluded articles discussing general health interventions without 
identification of pharmaceutical SCM interventions to improve health service delivery. In 
addition, I also excluded articles that did not have a focus in developing countries. Finally, I 
removed articles that focused on pharmaceutical SCM for the manufacturing sector only.  
Results 
 
Findings from the literature review included 22 papers with varying themes related to 
structural, leadership and systemic gaps affecting pharmaceutical supply chain management 
system (SCM) in developing countries. The results include five qualitative cross-sectional and 
observational studies, five quantitative studies, and four mixed methods studies. The other eight 
papers include editorials on pharmaceutical SCM, commentaries, literature reviews and a book 
chapter. Based on the focus of the systematic review, the findings were divided into six major 
themes focusing on (a) leadership and governance, (b) sustainability, (c) data management, (d) 
human resource management, (e) health service delivery, and (f) integration of SCM systems.  
a) Leadership and Governance: The context of weak leadership and governance 
structures in pharmaceutical SCM within developing countries was noted as a major 
challenge that needs attention (Chima & Homedes, 2015; Windisch, et al., 2011). The 
authors identified the lack of clear governance framework in pharmaceutical SCM within 
the different government institutions involved in antiretroviral therapy service delivery. 
These institutions are often not working together to coordinate pharmaceutical SCM 
activities (Windisch et al., 2011). Often, institutions duplicate roles that other institutions 




health environment (Chima & Homedes, 2015). Furthermore, the multiplicity of roles and 
duplication of efforts leads to inefficiencies, waste, and pharmaceutical system failures 
(Hasselback et al., 2014). Duplicity of efforts across agencies can also result in 
bureaucratic delays in obtaining approvals for SCM activities, with different government 
institutions having overlapping roles in providing strategic direction (Chima & Homedes, 
2015). In addition, the pharmaceutical SCM is often designed for convenience in 
management in governmental administrative structures. This design is inefficient, 
especially when technical and/or operational optimizations are not considered in the final 
implementation plan for SCM (Yadav, 2015). Furthermore, lack of a clear accountability 
structure in the governance system as result of role duplications creates room for poor 
resource management and product unavailability at the health facilities (Kohler, Mackey, 
& Ovtcharenko, 2014; Windisch et al., 2011). 
Garuba, Kohler, and Huisman (2009) to move the pharmaceutical system 
forward proposed the development and maintenance of institutional capacity along with 
governance structures and quality monitoring systems. Government should provide the 
vision, guidance and oversight for program implementation (Bornbusch, Dickens, Hart, & 
Wright, 2014). These are critical recommendations as system issues rooted in weak 
governance structures are often difficult to remedy except through a complete overhaul 
of the system or significant change in governance structures (Windisch et al., 2011). 
Problems related to the governance of pharmaceutical systems need to be 
acknowledged and addressed with participation of all stakeholders (Kohler et al., 2014). 
This is vital to generate the required consensus of stakeholders through a transparent 
decision-making process. 
b) Sustainability: Brown and Gilbert (2014); Chima and Homedes (2015), and Windisch et 




countries are donor-dependent, largely because of government inaction in addressing 
the needs of their population in these countries. Hence, the activities of the 
pharmaceutical SCM system follows the donor-driven agenda. These agendas are often 
targeted specifically at particular component of the health sector and short-term goals. 
As Windisch et al. (2011) noted, the dependence not only promotes fragmentation of the 
service delivery but also takes attention away from some critical health services like 
maternal and childhood illnesses that has higher morbidity and mortality but may not be 
part of the donor priority intervention in the supported health facilities. Poor 
accountability of donor funds by government had encouraged further bypassing of the 
existing government pharmaceutical SCM systems for direct interventions that will yield 
immediate results.  This results in further system fragmentation and makes the 
interventions unsustainable (Chima & Homedes, 2015; Windisch et al., 2011). Further, 
dwindling donors’ support for public health service delivery, due to donor-fatigue, is a 
concern that needs to be addressed in-county (Grepin, 2012). 
c) Data Management, Data Demand, and Information Use: Authors identified the need 
for reliable data to guide decision-making. Data are needed to ensure that decisions on 
SCM are based on evidence that will support uninterrupted service delivery (Brown & 
Gilbert, 2014). Poor recordkeeping practices often hampers the ability of the 
pharmaceutical SCM to calculate the period of product unavailability (stock out duration) 
for proper replenishment in subsequent supplies (Hasselback et al., 2014). This 
calculation is important to enable the service providers to receive a full complement of 
products needed to meet client demand. Findings from Hasselback et al. (2014) in 
Mozambique indicates an average of 78% missed product utilization opportunities as 
result of product unavailability. These missed opportunities (referred to as lost 




kits that were not met due to pharmaceutical product unavailability in clinics. The poor 
use of available data to guide product resupplies results in less timely access to health 
services for clients, and can also lead to greater travel costs, as some people must drive 
to other clinics or return multiple times to obtain needed services (Magadzire, Budden, 
Ward, Jeffery, & Sanders, 2014). This highlights the importance of evidence-based 
decision-making using available data to ensure that products are available in clinics 
based on client demand. 
Manual recordkeeping increases the burden on the health service providers to 
accurately document, store and retrieve available logistics data for decision-making 
(Silumbe & Kamuhabwa, 2015). Automating these data collections and use processes is 
beneficial, as timely logistics report submission will strengthen the overall 
pharmaceutical SCM with accurate data for resupply decisions (Hasselback et al., 2014; 
Jatau et al., 2015). However, any system that relies on electronic data collection must 
also include proper back up, as data loss can create a major challenge (Brown & Gilbert, 
2012). As noted by Chima and Homedes (2015) and Windisch et al. (2011), donor 
resources have assisted in the generation of logistics data to inform decision-making. 
Some of this is through electronic data automation processes. However, the vertical 
nature of these data collection mechanisms (i.e. multiple and independent channels of 
data collection from the same health facility) has made it more expensive and difficult to 
replicate in resource limited settings. Despite the cost implication, the availability and 
use of reliable data in pharmaceutical SCM improves the quality of public health 
practice. The continuous use of reliable data promotes the practice of evidence-based 
decision-making throughout the system (Daff et al., 2014). 
d) Human Resource Management: Authors noted that there were inadequate human 




Silumbe & Kamuhabwa, 2015). Limited supervision and training of staff further 
complicate inadequate human resources availability to provide services (Brown & 
Gilbert, 2014). Furthermore, there is poor retention of the staff who work in the SCM 
system. This is due to lack of performance incentives and poor remuneration within 
governmental institutions (Chima & Homedes, 2015). In addition, knowledge acquired 
from capacity-building exercises may not be used because staff are often redeployed to 
other positions where the new skills are no longer needed (Brown & Gilbert, 2012). This 
makes donors question resources committed to capacity building. For example, if on 
completion of a warehouse management training, the trainee is redeployed to an 
administrative office; the skill acquired from the warehouse management training 
becomes redundant. In addition, health managers are often limited in their ability to 
utilize available human resources within the public health system due to limited capacity 
and bureaucratic rules in meting out sanctions to underperforming staff (O’Neil, 2008; 
Yadav, 2015). The paucity of staff also adversely impacts on record keeping practices at 
the clinics to generate data needed to guide pharmaceutical product replenishment.  
Oqua et al. (2013) proposed developing a structured system of volunteers to fill staffing 
gaps in pharmaceutical SCM. The volunteers, with the right capacity building, can serve 
as local resources for service provision. In addition, these volunteers that are trusted 
within the communities can be used as a resource for storage, distribution and 
dispensing of the pharmaceutical products especially in emergency obstetrics care, as 
noted by Orobaton et al. (2015), in the use of Misoprostol (to prevent postpartum 
hemorrhage) and Chlorhexidine (cleaning of baby’s cord) as demonstrated in Sokoto 
State, Nigeria. 
e) Service Delivery: the availability of health products to support health service delivery is 




Magadzire et al., 2014; Oqua et al., 2013, Orobaton et al., 2015; Silumbe & 
Kamuhabwa, 2015). Health service delivery is often hinged on the right product being 
available in the right quantity at the right time, in the place and under the right condition 
and at the right cost of the clients (USAID|DELIVER PROJECT, 2011). The health 
workers serve as advocates between the clients and the health system by working to 
ensure uninterrupted pharmaceutical product availability (Magadzire et al., 2014). The 
availability of health products was found to motivate health workers as they have the 
resources needed to provide quality services to their clients (Adzimah, Awauag-Gyawu, 
Aikins & Duah, 2014).  
In pharmaceutical SCM managed by the government, emphasis is often placed 
on the procurement and warehouse infrastructure components with little attention to the 
operating costs (data management, distribution, maintenance etc.) of system that 
supports service delivery. This is often because the capital-intensive cost of purchasing 
warehousing equipment attracts political attention while the invisible costs that enable 
the system to function does not (Yadav, 2015). 
In addition, the distribution systems to move the pharmaceutical products to the 
clinics are sometimes not functional. This creates an inefficient system where health 
workers are compelled to travel to the warehouses to pick up pharmaceutical products 
(Yadav, 2015). Poor roads also create access barriers that prevent the transportation of 
products to health clinics. Private sector transporters that are contracted to provide 
distribution services may choose to avoid areas that can only be accessed through poor 
roads, thereby denying clients access to pharmaceutical products. Relying on the limited 
available public-sector transportation often increases the duration from when 
pharmaceutical products are needed to when they are available to the patients. 




the health system. This sometimes encourages them to seek alternative sources of 
healthcare that may not be of acceptable quality standards (Magadzire et al., 2014). The 
private sector distribution agents could address this problem through properly structured 
incentives (Palafox et al., 2014). However, this may increase the cost of service delivery 
in those rural locations thereby denying patients access to affordable healthcare. Access 
to health products can also be improved by referring patients to health centers closest to 
their residence with the required products (Magadzire et al., 2014). However, the client 
may not want to access services from nearby clinics where they are known due to 
stigma (especially for HIV/AIDS).  
In addition, the use of local networks of individuals (i.e. community health 
extension workers, retired nurses and lay health advisors in rural communities) that the 
clients can visit to access products have been noted to improve access to 
pharmaceutical product in Nigeria (Orobaton et al., 2015). The residence of these 
individuals has served as distribution points for emergency supplies in obstetrics care. 
This was documented in the use of Chlorhexidine and Misoprostol in rural communities 
in Sokoto State, Nigeria (Orobaton et al., 2015). Also, the use of vendor-managed 
mobile warehouse to increase access to pharmaceutical products have been 
documented in Senegal to increase access to pharmaceutical products (Daff et al., 
2014). These mobile warehouses visit clinics on a defined schedule to assess their 
requirements and replenish their pharmaceutical product need immediately. Authors 
noted that inappropriate management of available infrastructure and resources can 
result in dilapidated warehouses, expiration of products, and in some cases misuse of 
the product. This denies patients access to quality medicines needed for treatments.   
f) Integration: With the dwindling funds from the global community to support increased 




sustain quality service delivery (Amole et al., 2011; Grepin, 2012). Promoting efficiency 
in pharmaceutical SCM requires coordinating the use of all available resources through 
a planned integration process for the HIV/AIDS products SCM system among different 
public and private HIV/AIDS funding institutions (e.g. Government of Nigeria, PEPFAR, 
and The Global Fund). The benefits of integration may include increased economies of 
scale, increased flexibility and adaptability, improved efficiency and performance 
(Optimize, 2013). This is where the role of pharmaceutical SCM managers in shaping 
the system is crucial. The pharmaceutical SCM managers understand both patient 
needs and system gaps to meet the needs—hence their role is vital. Through an 
integrated pharmaceutical SCM system, people, processes, functions, and structure are 
linked and managed as an interconnected system (Bornbusch et al., 2014). 
System failure often occurs because of the institution of disease-specific 
interventions that are short term (Windisch et al., 2011). These short-term interventions 
in the procurement of pharmaceutical services are often not be applicable to other health 
programs. Mtonya and Chizimbi (2006) noted this in the use of World Bank guidelines 
for procurements of health products in Malawi despite perception by stakeholders that it 
was ‘cumbersome’. These short-term measures do not address program-wide 
bottlenecks for the public health program that will promote quality service deliveries 
(Windisch et al., 2011). Disease-specific interventions may include creating a 
warehousing system that is only used for antiretroviral drugs or distributions vehicle for 
drugs needed for malaria treatment. Efficiencies that would have been enjoyed through 
multiple uses of the same resource like a single warehouse or distribution infrastructure 
is lost to the system. Integration should include synchronizing or merging the processes 
within different components of SCM, such as data management. However, deciding 




happen (product or processes, full or segmented) is not an easy question to address 
(Optimize, 2013). This is where the contextual knowledge of the environment, technical 
understanding of the program and insight on available resources to support the 
integration process is paramount. Benefits of the integration process needs to be 
balanced with the goal of the program to ensure that the needs of the clients are always 
met (Optimize, 2013).  
Integration is not the panacea for all pharmaceutical SCM challenges as thought 
by some people (Optimize, 2013). There may still be benefit in SCM multiplicity to build 
in redundancies and agility as a risk management strategy (Bornbusch & Bates, 2013). 
The question though is at what cost and who will pay for the extra redundancies that 
may never be utilized? It is also important to note that poorly designed pharmaceutical 
SCM cannot be improved through integration. This will further complicate the system 
and clog the wheel of progress in making health products available in clinics. An 
effective supply chain should be able to respond to changes in health priorities of the 
environment, demographics, manufacturing, technology, and financing (Bornbusch et al., 
2014). 
In conclusion, the reviewed studies identified some of the bottlenecks in pharmaceutical 
SCM. However, none of the studies discussed comprehensive challenges and priority 
interventions to address all the components of pharmaceutical SCM as seen in the Nigerian 
context. These include policy formulation and implementation plan, product selection, availability 
and use at the clinics to support service delivery. Other gaps in effective pharmaceutical SCM in 
developing countries include human resource management and leadership. This is where 
further studies will be useful to close gaps in the pharmaceutical SCM system. Gaps to be 
addressed may include leadership and management, finance, human resources, procedures 




The results will inform discussions on long-term financing, human resources management for 
pharmaceutical SCM in Nigeria. Also, leadership and management strategies in pharmaceutical 
SCM within the government system beyond donor’s support will be reviewed as part of this 
research.    
Conceptual Framework 
 
To maintain effective pharmaceutical SCM system that will meet the purpose of the 
system, all the components of the system must work optimally as seen in the conceptual model 
(Figure 3). The model was adapted from the “Logistic Cycle” developed by John Snow, 
Incorporated on public health supply chain systems (USAID|DELIVER PROJECT, 2011). The 
model was further adapted based on the findings from the literature about needed components 
to ensure effective and efficient pharmaceutical SCM systems.  
Figure 3: Conceptual Model on Effective and Efficient Pharmaceutical SCM System  




Five major components of the pharmaceutical SCM cycle (Figure 3) work together in a 
synchronized and ordered fashion to achieve the purpose of the system. These components 
form the basis for the conceptual model for an efficient and effective pharmaceutical SCM 
system. The components include:  
(a) Product Selection: An integrated supply chain management system starts by selecting the 
right products needed to deliver services to the patients. This technical process involves 
clinicians, program managers, donors, and technical experts under government leadership. This 
process includes evaluations of new information on health products that may be introduced into 
the national formulary to optimize service delivery (Amole et al., 2011). The efficacy and cost-
effectiveness of such new products must be considered to ensure the patient received the best 
possible health services at an affordable price to the system. The output of such exercise is the 
standard treatment guideline (STG) for service delivery. Sometimes the committee responsible 
for selection is inactive, making this process cumbersome (Brown & Gilbert, 2012). 
(b) Quantification and Procurement: An integrated SCM system needs to estimate the 
quantity of the products needed over a period in the future to provide services and procure the 
products at the best possible value. This step also requires funding needed to obtain the 
required products when they are needed. This phase also includes a competitive process of 
acquiring the products to ensure the best value for the program and clients.  
(c) Inventory Management (Warehousing and Distribution): The integrated SCM system 
must have right processes to manage the products using standardized warehousing and 
distribution protocols. This helps to ensure that the products are not damaged and get to clinics 
where health workers can distribute them to appropriate clients in a timely and cost-efficient 




 (d) Serving the Clients: The last step in an integrated SCM system includes providing the 
appropriate services to the clients. This last step could also include counseling and referring 
clients for other services, and/or recommending new products or services to clients when 
appropriate. This frontline activity ensure the clients benefit from the pharmaceutical SCM 
whenever they need services. 
These four components work together in a cyclic process. Quality monitoring is critical 
for all the components. On the arrows that connect the different components is embedded 
quality monitoring. This is to ensure that each component is performing optimally to feed into the 
next component. Quality monitoring also provides the information needed to make needed 
changes or adjustments to continue quality service delivery. Quality monitoring is crucial as poor 
performance in any step of the SCM model affects the functioning of the other steps involved in 
making health products available to the clients. 
At the heart of the cyclic components is the fifth component that is the main engine that 
drives the other parts of the SCM system. The fifth component works with all the other 
components through a two-way feedback mechanism for continued monitoring and direction. 
Elements of the fifth component include effective leadership and management structure with 
clear vision, mission, and benchmarks to enable each SCM component performs optimally. In 
addition, the structure is driven by adequate (in number) and skilled (through capacity-building) 
human resources for day-to-day performance. The pharmaceutical SCM system also requires 
finances. The available finances need to be accounted for properly, with systems to minimize 
waste and improve performance. All the components should operate within established 
standard operating procedures (SOPs) that should be evaluated periodically to determine 
whether changes are needed. To implement the SOPs requires the availability of tools to 
gather data on the use of the products, when replenishment products are needed, and to 




decisions on financing, quality improvements, and evaluation of the pharmaceutical SCM. SOP 
provides timelines that are synchronized across functions within an integrated pharmaceutical 
SCM framework. The SOP also include use of standardized tools and protocols for data 
management, which will help synchronize performance and monitor requirements. Further, the 
SOP should include periodic performance evaluations. All these are needed to ensure that 
system performance is optimal using available resources within the system. The integration 
further involves the use a collaborative leadership and management structures with shared 
goals that will ensure that all components are functioning optimally.  
An effective and efficient pharmaceutical SCM system functions in an integrated 
framework (represented by the yellow circle surrounding the other components). The integrated 
framework should operate to coordinate and use all available resources within the system, both 
public and private. Using all resources can help improve efficiency in management of the 
pharmaceutical supply chain and enable the system be more adaptable to changes. For 
example, an integrated SCM system should use, when appropriate, private sector infrastructure 
(e.g. private for-profit entities that can lease their resources at cheaper rate to pharmaceutical 
SCM activities compared to commercial rates), public infrastructure (e.g. government resources 
that can be used for pharmaceutical SCM at minimal cost to the program), human resources, 
and financing. The integration process also includes maximizing available capacity in 
distribution of products from the manufacturer to the clients at the clinics to minimize waste. For 
example, maximizing the use of available distribution capacity could involve the utilization of 
available distribution spaces within a vehicle already scheduled to visit a health facility for 
another purpose. This will ensure the spaces in the vehicles are used in line with effective and 
efficient distribution protocol and that the pharmaceutical products get to the clients on time. It 
may also include optimizing distribution routes to ensure prompt and cost-effective delivery of 




avenues of getting the pharmaceutical products to clinics on time and in good condition. These 
may include air transportation, road networks, and distribution by waterways. The review 
process should also examine the physical condition of the roads, accessibility during different 
weather conditions (especially during rainy season), and security to maximize the use of 
available resources. The cost and timeliness of air transportation is also considered especially 
in emergencies.  
Furthermore, the SCM system operates within the context of an existing policy 
environment. The policy structure guides development of SOPs. This is to ensure that the SCM 
system operations are in line with set objectives of ensuring uninterrupted availability of the 
pharmaceutical products for specific health intervention. This policy structure determines the 
type of pharmaceutical products that will be supplied for use at specified health facility. The 
cadre of health workers often informs the decision on the type of product in the facility. For 
instance, the primary health centers that do not have access to pharmacists are not allowed to 
keep narcotic medicines for pain management.  
To meet these set objectives in line with the policy environment, the ‘six rights’ of 
pharmaceutical SCM system need to be met. In addition, an effective supply chain management 
system is designed to be agile to enable it respond quickly to changes in the environment by 
being easily adaptable. Some of the changes could include changes to patient demand (leading 
to changes in the amount of supplies needed); changes in treatment protocol leading to 








CHAPTER 3: METHODOLOGY 
Study Design: This study used an explanatory sequential mixed-method design (quantitative 
and qualitative) as described by Creswell (2013). The sequential mixed-method approach was 
necessary to explore the views of a wide variety of stakeholders at the national, state and health 
facility levels through surveys (quantitative). The survey result was used to guide detailed key 
informant interviews (qualitative) to further understand the survey findings and make proper 
qualitative recommendations for system improvements. The sequential mixed-method approach 
gave me an opportunity to seek the opinions of relevant stakeholders on implementable 
interventions to address identified challenges. 
Survey 
Survey Instrument: The survey (Appendices 2 and 3) included questions on the gaps to 
achieving the six rights of the pharmaceutical SCM system in the HIV/AIDS program. Based on 
the conceptual model (Figure 3) and literature review, I investigated the system elements of 
product selection, quantification and procurement, inventory management, serving client, 
logistic management information system, leadership and systems support (leadership, human 
resources management and accountability). I used the conceptual model to decide which 
components of the system to study (e.g. product selection) and literature review to decide which 
specific barriers and potential solutions to examine for each component, developing separate 
barrier and solution items as appropriate for ARVs and RTKs. These were used to develop the 
survey instrument, taking note of issues that applicable in the SCM system for ARVs and RTKs 




Conceptual model to support uninterrupted product supplies and improvements needed in the 
system. 
The survey asked respondents a series of questions about the functioning of the current 
SCM system (using scoring scale—5-point Likert scale; 5 = Very Important; 4 = Important; 3 = 
Moderately Important; 2 = Slightly Important; 1 = Not Important; 0 = Don’t Know), along with 
open-ended questions about other disruptions and/or proposed solutions in the supply chain 
system (Cummings & Hulley, 2007). The survey instrument was in two versions. I shared one 
version with potential respondents managing the supply chain system for antiretroviral drugs 
(ARVs) and another version with those managing HIV rapid test kits (RTKs). I developed two 
versions of the survey to address the unique characteristics of each product type (e.g. quality 
testing challenges for RTKs and adverse drug reaction for ARVs). In addition, the use of two 
versions enable me to reach out to respondents that work with each product type in the supply 
chain system. 
I pre-tested the survey instrument on five potential respondents to receive inputs on 
clarity of the questions and how long it took to complete. Based on their feedback, I further 
revised the survey content for clarity (Hulley and Cummings, 2001). I submitted the final version 
of the survey instrument (Appendices 2 and 3) along with other documentation and obtained 
ethical approvals from the University of North Carolina at Chapel Hill, Institution Review Board 
(IRB)-17-2071 and National Health Research Ethics Committee, Nigeria (NHREC)- 
NHREC/01/01/2007-26/10/2017. 
Sampling Method: I used stratified purposive sampling in conducting the survey to obtain a 
representative sample. I stratified the sample by product type (ARVs and RTKs), geographic 
locations (Northern Nigeria, Southern Nigeria, and Federal Capital Territory), and type of 




Sampling Frame: The sampling frame included persons that work within the pharmaceutical 
SCM system for the HIV/AIDS program in Nigeria at three different levels (i.e. health facility, 
states, and federal levels). To obtain a representative sample, I purposively sent the survey to 
respondents in four states - two states each in the North of Nigeria and two in the South - as 
well as in the Federal Capital Territory, Abuja. These included personnel in government health 
systems, donor agencies, local and international non-governmental organizations (NGOs) and 
private sector organizations supporting the pharmaceutical SCM system for the HIV/AIDS 
program in Nigeria. The HIV/AIDS pharmaceutical SCM systems within states in Northern and 
Southern zones in Nigeria share similar characteristics based on the nationally designed 
system. However, there are marked geographical differences in the pharmaceutical SCM 
system across the two zones. Hence, selecting representative samples of two states within 
each zone gave the needed representation to identify gaps and propose solutions. For example, 
in the Northern states, HIV/AIDS product distribution timeline is longer because of larger 
landmass and distances between the warehouses and the health facilities. In Southern Nigeria, 
the distribution timeline is shorter because of smaller landmass and closeness of the health 
facilities to warehouses. However, in Southern Nigeria, during the rainy season, it is more 
difficult to deliver health products because of flooding of the roads compared to Northern with 
better access road network. 
To find a representative sample, I obtained the meeting attendance lists from national 
and state-level pharmaceutical SCM coordination meetings for the HIV/AIDS program in the last 
12 months. These meetings are held every quarter at the federal and state levels. At the end of 
these meetings, participants receive the attendance lists from these meetings along with the 
meeting minutes that are publicly available. Representatives of the various stakeholders 
involved in HIV/AIDS pharmaceutical SCM were usually in attendance at these meetings. I also 




recommendations of my colleagues in the states working directly with these health facilities. I 
used this larger list of potential respondents to identify people to contact in health facilities.   
Sample Size: I planned to obtain feedback from 40 to 60 respondents. I assumed a 50% 
response rate and sampled twice the number of respondents I was targeting for study. Table 1 
below had my sampling framework. 
Table 1: Number of Surveys Sent and Received      
Geography State Local areas Type of organization 
Number of 
respondents who 
were sent survey 
Number of people 
who received the 
survey* 
North Benue Makurdi Clinics, NGOs, SMOH 21 21 
  Gboko Clinics, NGOs, SMOH 6 6 
North Kaduna Kaduna Clinics, NGOs, SMOH 40 28 
  Kafanchan Clinics 17 12 
All Northern 
participants 
   
84 67 
South Lagos Ikeja 
Clinics, NGOs, SMOH, 
Private Sector 
18 16 





Clinics, NGOs, NGO, 
Private sector 
10 10 
  Obudu/Ogoja Clinics 7 5 
All Southern 
participants  
   
44 40 
Federal FCT AMAC 
Clinics, FMOH, NGO, 
Private sector, Donors 
98 88 
  Gwagwalada Clinics 10 10 
All Federal 
participants 




   
236 205 
NGOs – non-governmental organization; SMOH – state ministry of health; FMOH – federal ministry of health. 
*This column excludes respondents who had bounced surveys (i.e., surveys were not able to be delivered.) 
 
Data Collection: I contacted respondents via e-mails. First, I asked for an introductory 
communication via email from the supply chain leaders in the states to all potential respondents 
letting them know they would be receiving a survey from me. The introductory communication 
stated that participation was confidential and voluntary while encouraging them to participate. 




the e-mail outreach, I gave options for the potential respondents to complete the instrument 
online in Qualtrics or return the attached Microsoft Word document to me via the provided e-
mail address. I also gave them the option of filling out a hard copy that would be couriered to 
them at no cost. I issued the survey instrument through Qualtrics e-mail and attached the 
Microsoft Word version on the e-mail. I also followed up with periodic e-mail reminders to 
encourage participation and increase response rate (Dillman, Symth, & Christian, 2014). I also 
informed the potential respondents that they had different options of returning the completed 
survey as suggested by Dillman et al. (2014). Respondents that had sent their responses via 
Qualtrics received an acknowledgement and appreciation e-mail. I conducted the survey over a 
6-weeks period. I received all completed instruments via electronic submissions only (e-mail, 
and Qualtrics). Summary of respondents that received the survey and those that completed it is 
on Table 2.  
Table 2: Number of Surveys Received and Completed by Geography and Setting 
 Number who received 
surveys 
Number who completed 
survey 
Response rate (%) 
Geography 
  North 67 21 31 
  South 40 11 28 
  Federal 98 43 44 
 205 75 37 
Respondent Work Setting 
  Clinics 126 32 25 
  NGOs 45 27 60 
  SMOH 14 7 50 
  FMOH  7 3 43 
  Private sector 6 3 50 
  Donors 7 3 43 
Total 205 75 37 
NGOs – non-governmental organization; SMOH – state ministry of health; FMOH – federal ministry of health. 
The survey response rate was 32% for antiretroviral drugs and 33% for HIV rapid test 
kits giving a cumulative average of 32% overall responses for those that received the survey as 





Table 3: Survey Response Rates by Type of HIV/AIDS Products (ARVs or RTKs) 
Description ARVs RTKs Summary 
Potential respondents 159 77 236 
Bounced e-mails 18 13 31 
Survey transmitted 141 64 205 
Finished survey 45 21 66 
Completion % for transmitted survey 32% 33% 32% 
 
More than four-fifths of respondents (85%) have more than 3 years experience in 
HIV/AIDS supply chain in Nigeria. In addition, 30% of the respondents work at the health 
facilities, 24% at the states, 32% at the federal level while other work across multiple levels of 
the system. Also, 33% work in Northern Nigeria, 20% in Southern Nigeria, and 47% work in the 
FCT. On the types of organizations, 32% work with the government, 41% with NGOs, 10% with 
donor agencies, 14% work in the private sector while 3% work in other organizations.  
Data Analysis: I analyzed the results using Qualtrics analytical functions and Microsoft Excel 
(McFedries, 2013). I summarized and displayed the survey results in tables and bar charts (for 
multiple variables). I received very few qualitative responses. For the qualitative responses in 
the survey instrument, I read the feedback to extract emerging themes. These themes I grouped 
under the theoretical supply chain component (e.g. product selection) where they were reported 
to provide appropriate context. I used the quantitative data and qualitative results from the 
survey to form the key informant interview guide. 
 
Key Informant Interviews 
 
Key Informant Interview Guide: I used a semi-structured interview guide (Appendix 4) to gain 
insight on the barriers and potential solutions found in the quantitative analysis (Gill, Stewart, 
Treasurer, & Chadwick, 2008). The guide further gave prompts for the respondents to validate 
barriers and solutions collated from the survey while proposing further barriers and solutions to 




challenges that had hindered the implementation of recommendations from earlier studies. I 
used this approach to develop pragmatic recommendations and the plan for change. I divided 
the KII guide into eleven parts with sub-sections to review major components of the supply 
chain system and the needed enabling environment for supply chain performance. 
The guide aligned with the research theoretical framework but also allowed respondents 
to identify other issues that impacted on the current state of the Nigeria HIV/AIDS supply chain 
system.  The guide was approved by both UNC (17-2071) and Nigeria IRB 
(NHREC/01/01/2007-09/03/2018B).  
Sample Recruitment: I sent the first personalized e-mail to all potential respondents to indicate 
their willingness and availability to participate. The initial e-mail included the informed consent 
form that detailed the KII protocol. I gave options to potential respondents to either be 
interviewed in-person or over the phone at a convenient time and venue to give.  My intent was 
to give them the required flexibility to encourage their participation in the study. I followed up the 
first e-mail with further e-mail reminders. The reminders were followed up with a phone call to 
those that indicated they should be called to set up the interview. 
Sample Frame, Sampling Method, and Sample Size: Respondents included health supply 
chain managers within the government institutions, donor communities, local and international 
organizations working in HIV/AIDS supply chain based on sampling frame I used for the survey. 
I used purposive sampling method for respondents’ recruitment. For the key informant 
interviews, I planned to recruit between 16 and 24 respondents. The plan was to target about 
70% of the respondents from the Federal Capital Territory (FCT) while 15% each will come from 
the Northern and Southern States. This was because the federal level personnel in the FCT 
make most of the national policy decisions for the HIV/AIDS pharmaceutical SCM. However, I 




in Nigeria are independent of the federal government on health matters. I conducted the 
interviews over 5 weeks to accommodate the schedule of respondents. Based on purposive 
sampling, I reached out to 26 potential respondents from the federal and state levels via e-mails 
(Table 4). 
Table 4: Number of Key Informant Interview Respondents     




Number of respondents who 
participated in interview 
Coverage 
(%) 
Geography     
  North 3 11 2 10 
  South 8 31 7 33 
  Federal 15 58 12 57 
 26 100 21 100 
Respondent’s 
Work Setting 
    
  NGOs 14 53 11 52 
  SMOH 5 19 4 19 
  FMOH  3 12 2 10 
  Private sector 1 4 1 5 
  Donors 3 12 3 14 
Total 26 100 21 100 
 
In total, 24 of the 26 potential respondents responded to the second follow-up e-mail 
while two respondents did not respond. I did not follow up further after a second reminder e-
mail. Of the 24 that responded to the follow up e-mails, I interviewed 21 respondents while three 
were not available within the timeframe. I sent participants a summary of the survey findings 
and the KII guide at least 48 hours before the interview.  
In total, I interviewed 21 respondents. Nine were from the state level (43%) and twelve 
were from the national level (57%). This gave a proper representation of the federal and state 
level responses in the results. In addition, six respondents worked for the government (29%), 
three respondents worked for donor organizations (14%), eleven respondents worked with non-
governmental organizations (52%) implementing health service delivery and one work with 
private organization (5%) implementing supply chain programs in Nigeria. The respondents’ 




respondents had a cumulative of 164 years of experience in the public health supply chain 
space in Nigeria. The respondents’ experiences cut across all aspect of the Nigeria HIV/AIDS 
supply chain from the clinics to the state and federal levels. They also had a blend of 
experiences working with governments, donors, and Non-Government Organizations (NGOs) 
supporting HIV/AIDS supply chain and service delivery in Nigeria.  
Data Collection: I conducted one-on-one in-depth interviews, in-person and by telephone 
(Gill et al., 2008). All of the respondents consented to the interview. Most of the interviews took 
between 30 - 45 minutes. I labelled voice recordings “respondent 1” to “respondent 21” and 
stored the files in a computer with strong password. I transcribed recordings verbatim in 
Microsoft Word documents for analysis.    
Data Analysis: I used content analysis to analyze the data. First, I moved the transcript from 
MS Word to MS Excel following the structure of the KII guide. This enabled me to easily 
navigate through the patterns using MS Excel functionality to highlight common themes within 
MS Excel rows and columns. I read the transcripts in MS Excel to review emerging themes that 
I highlighted with different colors of text for easy identification of patterns for the first three 
transcripts. This guided the development of a codebook based on emerging themes from the 
responses that was linked to the conceptual framework. The codebook enabled me to display 
the 21 transcripts in Microsoft Excel to easily see patterns and themes and cluster them 
together for analysis. I also analyzed differences, similarities, or outliers in the opinions of the 
respondents, or among types of respondents. 
To validate the codebook used in the analysis, I recruited a second coder from UNC 
DrPH Cohort 12, to review the analysis. The second coder studied three transcripts using the 
codebook and themes that emerged from the data. For example, an emerging theme on barriers 




revision of treatment guidelines and reporting. The emerging sub-themes included poor 
dissemination of the treatment guidelines to the clinics by the federal government and poor 
reporting of adverse drug reactions from the clinics to the national regulatory authority. The 
second coder reviewed the themes and sub-themes, and further confirmed if findings from the 
transcripts aligns with the codebook and analysis already developed. For the three transcripts 
reviewed by the second coder, a Cohen’s Kappa coefficient of 0.9 was achieved with 99% 








Findings from the surveys are contained in the bar charts below for each product type. 
The charts highlight the barriers and solutions identified by the respondents. The findings were 
arranged by each of the six components of the supply chain management system and by 
product type. The results focus on the barriers and solutions that were identified by respondents 
as very important or important. For the purpose of further analysis of the findings, I identified the 
priority barriers and solutions using 85% as the threshold (i.e. 85% of respondents needed to 
have identified a specific barrier or solution as very important or important). While this number 
was somewhat arbitrary, I used it to identify the top barriers and/or solutions.  Also, I included 
some of the additional comments provided by respondents in the open-ended section of the 
surveys for barriers or solutions. These were comments noted by respondents that also came 




The RTKs respondents were asked about major barriers to product selection (Figure 4). 
More than 85% of respondents identified four barriers as “important” or “very important”: poor 




poor knowledge and use of various RTKS types (91%), failure to distribute national testing 
algorithms to health workers (86%), and lack of funding to procure new RTKS (86%).   
 Figure 4: RTKs – Product Selection (Barriers)                                                                                                                                                                
 
These corresponds with qualitative feedback from respondents. For example, one 
person highlighted that poor engagement with clinic health workers when new products were 
being introduced made it difficult for the workers to understand the protocol for use of the new 
product and report on their quality performance in line with established standards. One 
respondent noted that pressure from manufacturers to include their products into the national 
testing algorithm resulted in limited stakeholder engagement by the Government leadership in 




Similarly, the ARVs respondents were asked about major barriers to product selection 
(Figure 5). More than 85% of respondents identified two barriers as “important” or “very 
important”: Poor reporting of adverse drug reactions on new ARVs to National Regulatory 
Authority (93%), and national standard treatment guidelines for ARVs not distributed to health 
workers (88%). Like the qualitative feedback from the RTKs respondents, for the ARVs several 
respondents highlighted limited involvement in the decision-making process by health workers 
that are using these products daily for service delivery. In addition, two respondents identified 
lack of clear protocols for inclusion of new ARVs regimen into the national guideline that often 
results in wastages as legacy products are not completely used up while new ones are being 
introduced. Also, new treatment guidelines for introduction of new regimens are not 
disseminated promptly.  








On solutions to the identified barriers on the product selection component, RTKs and 
ARVs respondents proposed solutions that directly related to the barriers. RTKs respondents 
were asked about solutions on identified barriers to product selection (Figure 6). More than 85% 
of respondents identified five solutions as “important” or “very important”: Reduced cost new 
RTKs by manufacturers (86%), increased funding from Government at all levels for new RTKs 
procurements (91%), capacity building on use of various RTKs types (96%), prompt reporting of 
RTKs failed quality control tests to National Regulatory Authority (96%), and prompt 
dissemination of HIV RTKs testing algorithm to health workers (91%). From the qualitative 
responses, a respondent identifed capacity-building of local manufacturers to minimize cost of 
production as a solution. 






  Also, ARVs respondents were asked about solutions on identified barriers to product 
selection (Figure 7). More than 85% of respondents identified three solutions as “important” or 
“very important”: Capacity-building on use of various ARVs types (85%), prompt reporting of 
ARVs adverse drug ractions to National Regulatory Authority (93%), and prompt dissemination 
of ARVs standard treatment guidelines to health workers (90%). From the qualitative feedback, 
effective stakeholder engagement in product selection and development of local capacity for 
ARVs production were identified by two respondents as solutions to the identified barriers. 
Figure 7: ARVs Product Selection (Solutions) 
 
Quantification and Procurement 
Barriers 
Respondents to the RTKs questions were also asked about major barriers to 
Quantification and Procurement (Figure 8). As a reminder, quantification is an ongoing process 




period in the future. The projection is intended to ensure uninterrupted supply of products to the 
health service providers and clients. More than 85% of respondents identified five barriers as 
“important” or “very important”: Limited use of RTKs quantificaton results to inform procurement 
in Government system (91%), inadequate funding to purchase RTKs needs identified in 
quantification (90%), RTKs quantification information not provided timely for donors 
procurement decisoion (91%), RTKs quantificatio information not provided timely for 
Government procurement decisions (86%), and inaccuate logistics data used for quantification 
(86%).  
Figure 8: RTKs Quantification and Procurement (Barriers) 
 
 
Similarly, respondents to the ARVs questions were also asked about major barriers to 
Quantification and Procurement (Figure 9). More than 85% of respondents identified two 
barriers as “important” or “very important”: Limited use of ARVs quantification result to inform 




quantification (87%). On the qualitative feedback, a respondent noted that the quantification 
exercises were not properly supervised for prompt completion and timeliness of the results.  





Similar to what respondents reported with product selection, the solutions to the barriers 
identified for quantification and procurement were directly related to the barriers. More than 85% 
of RTKs respondents identified all seven solutions as “important” or “very important” (Figure 10): 
Use of RTKs quantification results to inform procurement within donor agencies (95%), use of 
RTKs quantification results to inform procurements within Government system (96%), prompt 
mobilization of funds required to procure RTKs from result of quantification (91%), prompt 
dissemination of RTKs quantification results within a defined period to donors (100%), prompt 




training of Nigerians on RTKs quantification processes and tools (100%), and provision of 
accurate RTKs logistics data for quantification (96%).  
Figure 10: RTKs Quantification and Procurement (Solutions) 
 
On the ARVs quantification and procurement, more than 85% of ARVs respondents 
identified six solutions as “important” or “very important” (Figure 11): Use of ARVs quantification 
results to inform procurement within donor agencies (96%), use of ARVs quantification results to 
inform procurement within Government system (87%), prompt mobilization of funds required to 
procure ARVs from the result of quantification (92%), prompt mobilization of funds required to 
procure ARVs from the result of quantification (92%), prompt dissemination of ARVs 
quantification results within a defined period to donors (90%), training of Nigerians on ARVs 
quantification processes and tools (86%), and provision of accurate ARVs logistics data for 
quantification (96%). One respondent proposed a stepwise follow up in all the quantification 
processes and effective engagement with Government for prompt disbursement of budgetary 








Warehousing and Distribution 
Barriers 
On the Warehousing and Distribution services, more than 85% of RTKs respondents 
identified three barriers as “important” or “very important” (Figure 12): Poor vehicular access 
road to clinics (86%), late delivery of RTKs to clinics (90%), and failure to follow the first-to-






Figure 12: RTKs Warehousing and Distribution (Barriers) 
 
 
         On ARVs Warehousing and Distribution barriers, more than 85% of respondents identified 
one barrier as “important” or “very important” (Figure 13): Late delivery of ARVs to clinics (93%). 
On the qualitative responses, a respondent identified the distribution agents’ poor 
communication skills as a barrier while two respondents noted lack of human resource capacity 













              On solutions to the identified Warehousing and Distribution barriers, more than 85% of 
RTKs respondents identified three solutions as “important” or “very important” (Figure 14): Use 
of different vehicle types to access remote clinics (91%), implementation of the first-to-expire 
first-out guidelines (90%), and automation of warehousing management system for pick-and-








Figure 14: Warehousing and Distribution (Solutions) 
 
 
Similarly more than 85% of ARVs respondents identified one solution as “important” or 
“very important” (Figure 15): Implementation of the first-to-expire first-out guidelines (91%). On 
the qualitative responses, near real-time monitoring of the distribution agents to ensure 
compliance with established distribution protocols was identified as a solution along with 









Figure 15: ARVs Warehousing and Distribution (Solutions) 
 
 
Logistics Management Information System 
Barriers 
                Respondents to the RTKs questions were asked about major barriers to logistics 
management information system. About 85% or more of respondents identified three barriers as 
“important” or “very important” (Figure 16): Inadequate infrastructures for RTKs logistics data 
submission (85%), late submission of RTKs logistics data to higher level (86%), and poor SCM 






Figure 16: RTKs Logistics Management Information System (Barriers) 
 
              Respondents to the ARVs questions were also asked about major barriers to logistics 
management information system. More than 85% of respondents identified two barriers as 
“important” or “very important” (Figure 17): Inaccurate ARVs logistics data for decision-making 
















              On solutions to the identified barriers on logistics management information system 
more than 85% of RTKs respondents identified five solutions as “important” or “very important” 
(Figure 18): Provision of infrastructures for RTKs logistics data submission (100%), use of 
accurate RTKs logistics data for decision-making (95%), timely submission of RTKs logistics 
data (95%), provision of supply chain management tools for RTKs record keeping (95%), and 








Figure 18: RTKs Logistics Management Information System (Solutions) 
 
 
              Similarly, about 85% or more of the ARVs respondents identified four solutions as 
“important” or “very important” (Figure 19): Use of accurate ARVs SCM data for decision-making 
(98%), timely submission of ARVs SCM data (94%), provision of SCM tools for ARVs record 










Figure 19: ARVs Logistics Management Information System (Solutions) 
 
 
Serving the Clients 
Barriers  
             Respondents to the RTKs questions were asked about major barriers to serving the 
clients.  About 85% or more of respondents identified two barriers as “important” or “very 
important” (Figure 20): Poor adherence to manufacturer’s specification on RTKs use (86%), and 






Figure 20: RTKs Serving the Clients (Barriers) 
 
 
           However, none of the barriers in serving the clients from ARVs respondents reached the 
85% threshold of importance (Figure 21). From the qualitative feedback, poor staff pay was 
identified as a barrier to serving clients. Also, limited knowledge of the staff on antiretroviral 
therapy and the inability of manufacturers to meet global demands with constant changes in 
















              On solutions to the identified barriers to serving the clients about 85% or more of RTKs 
respondents identified five solutions as “important” or “very important” (Figure 22): 
Refurbishment of RTKs storage space at clinics (85%), practicing first-to-expire first-out 
guideline in utilizing RTKs (95%), strict adherence to manufacturer’s specification on use of 
RTKs (95%), planned outreach testing using RTKs (85%), and increased awareness and 








Figure 22: RTKs Serving the Clients (Solutions)                                           
 
 
              On solutions to the identified barriers to serving the clients more 85% of ARVs 
respondents identified one solution as “important” or “very important” (Figure 23): Practicing 
first-to-expire first-out guideline dispensing ARVs (86%). From the qualitative feedback, 
increased compensation package for the health workers and increased storage space at the 













Leadership and Systems Support 
Barriers  
           On leadership and systems support, respondents to the RTKs questions were asked 
about major barriers. About 85% or more of respondents identified two barriers as “important” or 
“very important” (Figure 24): Inadequate accountability of RTKs in the public-sector HIV 
pharmaceutical and laboratory supply chain management system (85%), and inadequate 







Figure 24: RTKs Leadership and Systems Support (Barriers) 
 
 
Similarly, respondents to the ARVs questions were asked about major barriers.  More 
than 85% of the respondents identified one barrier as “important” or “very important” (Figure 25): 
In adequate funding to support LMCU task (93%). From the qualitative feedback, lack of full 













          On solutions to identified barriers on leadership and systems support, about 85% or more 
of the RTKs respondents identified six solutions as “important” or “very important” (Figure 26): 
Development of framework for supply chain management system modifications (90%), 
structured and effective procurement and supply management technical working group 
meetings (91%), establishment of accountability and supervisory framework for HIV SCM 
system resources (91%), provision of funding to support LMCU task (95%), development of 









                Similarly, about 85% or more of the RTKs respondents identified four solutions as 
“important” or “very important” (Figure 27): Establishment of accountability and supervisory 
framework for HIV supply chain management resources (90%), provision of funding to support 
LMCU task (96%), development of clear scope of work for NPSCMP (90%), and development of 













Table 5 summarizes the barriers and solutions that the respondents reported as very 
important or important on both the ARVs and RTKs surveys that attained the 85% threshold. 
The summary of these major respondents’ feedback on barriers and solutions revolves around 
four themes: data management and use, leadership and funding, stakeholders’ coordination, 
and service delivery. 
The major barriers and solutions that attained the 85% threshold are grouped under 
these themes to highlight their similarities and relationships in the survey. In addition, the 
themes highlighted in the survey were the basis of the key informant interview guide. Thus, 




These themes are interconnected and linked to several aspects of the SCM system as 
contained in the Conceptual Model for an Effective and Efficient Pharmaceutical Supply Chain 
Management Cycle (Figure 3). For example, data management and use challenges were linked 
to unavailability of tools to collect logistics data (Tools and Data for Decision-making) and 
limited human resource capacity (Skilled & Adequate Human Resources). This impact directly 
on ability to make the right decision on quantities of the health products needed for service 
delivery (Quantification and Procurement). This poor documentation further results in service 
disruption due to health product unavailability at the clinics (Serving the Clients). Also, limited 
leadership (Effective Leadership) and funding support from the government impedes 
stakeholders’ coordination and accountability (Finance & Accountability). The consequence was 
the reported gap in information sharing among the different levels in the system (i.e. federal, 
state and clinics), which in turn leads to problems in giving quality services to the clients 
(Serving the Clients).  
Similarly, the solutions to address the data management challenges are linked directly to 
provision of infrastructure in terms of logistics tools (Tools and Data for Decision-making) and 
capacity building (Skilled and Adequate Human Resources). Furthermore, prompt sharing of 
national guidelines (Product Selection) and quantification results with relevant stakeholders is 
essential for decision-making on health product needs (Quantification and Procurement). These 
will empower the stakeholders with relevant information to ensure continuous availability of 
health products at the clinics (Warehousing and Distribution). Also, the need for Government 
leadership and funding is crucial through clear accountability structures (Effective Leadership & 
Management Structures). This will ensure that resources invested in capacity building leads to 
meaningful impact through improved service delivery (Serving the Clients). 
To address specific major themes from the survey, respondents identified more top 




data reporting and inadequate funding to procure HIV/AIDS products. Based on the views of the 
respondents, the barriers around government funding, significant reliance on donors, inaccurate 
data and reporting problems, and poor information dissemination were consistency identified 
both in the RTKs and ARVs survey responses and in written feedback provided by the 
respondents. Many respondents noted delay in the supply of needed health commodities to the 
clinics to support service delivery. The delay results in service disruption especially in the use of 
RTKs. Other themes that were highlighted as underlying reasons for the inability of the supply 
chain system to meet clients’ health needs was the rapid changes in antiretroviral drugs 
regimens with introduction of new medications coupled with the inability of the manufacturers to 
produce the quantity of new drugs needed to meet the need. This creates program disruptions 
because the delayed procurement cascades into late deliveries resulting in the unavailability of 
antiretroviral drugs at the clinics.  
The solutions to the identified barriers closely followed the barriers. Capacity-building 
and increased government funding to procure health products and support the supply chain 
system were prominent themes. In addition, respondents suggested greater capacity building of 
health workers on supply chain practices at the clinics and warehouses, and enhanced data 
visibility for decision-making (e.g., timely availability and use of data). Proactive engagement of 
more stakeholders in the selection of new products along with government support for local 









Table 5: Summary of Survey Top Barriers and Solutions 
  
Top Priority Barriers 
(>85% rated as Very 
Important or Important) 
Rapid Test Kits (% of 
respondents rating the barrier as 
very important or important) 
Antiretroviral Drugs (% of 
respondents rating the barrier as 




















 Inaccurate data 
Inaccurate RTKs SCM data used 
for quantification (86%) 
Inaccurate ARVs logistics data used 
for quantification (87%) 
Poor SCM record keeping practices 
on RTKs utilization (100%) 
Inaccurate ARV logistics data for 
decision-making (89%) 
Poor reporting 
Poor reporting of failed quality 
controls with new RTKs to National 
Regulatory Authority (91%) 
Poor reporting of adverse drug 
reactions on new ARVs to National 
Regulatory Authority (93%) 
Late submission of RTKs logistics 
data to higher level (86%) 
Late submission of ARVs logistics 
data to higher level (89%) 
Poor data use 
Limited use of RTKs quantification 
results to inform procurement in 
Government system (91%) 
Limited use of ARVs quantification 
results to inform procurement within 





















Lack of funding to procure new 
RTKs (86%) 
Inadequate funding to support 
LMCU task (93%) 
Inadequate funding to purchase 
RTKs needs identified in 
quantification (90%) 
  
Inadequate funding to support 
LMCU task (95%) 
  
Inadequate infrastructure 
Poor vehicular access road to 
clinics (86%) 
  
Inadequate infrastructure for RTKs 
logistics data submission (85%) 
Poor performance 
management 
Late delivery of RTKs (90%) 
Late delivery of ARVs to clinics 
(93%) 
Inadequate accountability 
Inadequate accountability of RTKs 
in the public sector HIV 
pharmaceutical and laboratory 


























Limited human resources 
capacity 
Poor knowledge on the use of 
various RTKs type (91%) 
  
Failure to follow the first-to-expire 
first-out guideline in managing 
RTKs (91%) 
  
Poor adherence to manufacturer’s 
























RTKs National HIV Testing 
algorithm not disseminated to 
health workers (86%) 
National Standard Treatment 
Guideline for ARVs not distributed to 
health workers (88%) 
RTKs quantification information not 
provided timely for Government 





RTKs quantification information not 
provided timely for Donor’s 















Unavailability of RTKs in the clinics 
(85%) 
  
       
 
Top Priority Solutions 
(>85% rated as Very 
Important or Important) 
Rapid Test Kits (% of 
respondents rating the solution 
as very important or important) 
Antiretroviral drugs (% of 
respondents rating the solutions 





















Submission and use of 
accurate data 
Provision of accurate RTKs 
logistics data for quantification 
(96%) 
Provision of accurate ARVs logistics 
data for quantification (96%) 
Provision of accurate ARVs 
logistics data for quantification 
(96%) 
Timely submission of ARVs SCM 
data (94%) 
Use of accurate RTKs logistics 
data for decision-making (95%) 
Use of accurate ARVs SCM data for 
decision-making (98%) 
Timely submission of RTKs 
logistics data (95%) 
Clinic staff accountability of accurate 
and timely ARV record keeping 
(89%) 
Data use for decision 
making 
Use of RTKs quantification result to 
inform procurement within 
Government systems (96%) 
Use of ARVs quantification results to 
inform procurement within 
Government system (87%) 
Use of RTKs quantification results 
to inform procurement within Donor 
agencies (95%) 
Use of ARVs quantification results to 
inform procurement within Donor 
agencies (96%) 
Improved record keeping practices 






















Increased funding from 
Government at all levels for new 
RTKs (91%) 
Prompt mobilization of funds 
required to procure ARVs from the 
result of quantification (92%) 
Prompt mobilization of funds 
required to procure RTKs from 
result of quantification (91%) 
Provision of funding to support 
LMCU task (96%) 
Provision of funding to support 
LMCU task (95%) 
  
Reduced cost of new 
products 
Reduced cost of new RTKs by 
manufacturers (86%) 
  
Provision of infrastructure 
Use of different vehicle type to 
access remote clinics (91%) 
Provision of SCM tools for ARVs 
record keeping (85%)  
Provision of infrastructure for RTKs 
logistics data submission (100%) 
  
Provision of supply chain 
management tools for RTKs record 
keeping (95%) 
  
Refurbishment of RTKs storage 
space at clinics (85%) 
  
Automation of warehouse 
management system for pick and 




























Capacity-building of health 
workers 
Capacity building on use of various 
RTKs types (96%) 
Capacity building on use of various 
ARVs types (85%) 
Training of Nigerians on RTKs 
quantification process (100%) 
Training of Nigerians on ARVs 
quantification processes and tools 
(86%) 
Strick adherence to manufacturer’s 
specification on use of RTKs (95%) 
  
Increased awareness and 





Implementation of first-to-expire 
first-out guidelines (90%) 
Implementation of first-to-expire first-
out guidelines (91%) 
Practicing of first-to-expire first out 
guideline in utilizing RTKs (95%) 
Practicing first-to-expire first out 
guideline in dispensing ARVs (86%) 






















Prompt dissemination of 
guidelines 
Prompt dissemination of HIV RTKs 
testing algorithm to health workers 
(91%) 
Prompt dissemination of ARVs 
standard treatment guidelines to 
health workers (90%) 
Prompt information 
dissemination 
Prompt dissemination of RTKs 
quantification results within a 
defined period to Government 
(95%) 
Dissemination of ARVs 
quantification results within a 
defined period to the Donors (90%) Prompt dissemination of RTKs 
quantification results within a 
defined period to Donors (100%) 
Development of 
coordination structure 
Establishment of an accountability 
and supervisory framework for HIV 
SCM resources (91%) 
Establishment of an accountability 
and supervisory framework for HIV 
SCM resources (90%) 
Development of a framework for 
SCM system modifications (91%) 
Development of clear scope of work 
for NPSCMP (90%) 
Structured and effective PSM TWG 
meetings (91%) 
Development of clear scope of work 
for LMCU (86%) 
Development of clear scope of 
work for NPSCMP (90%) 
  
Development of clear scope of 













Reporting of failed quality 
control tests 
Prompt reporting of RTKs failed 
quality control tests to National 
Regulatory Authority (96%) 
  
Prompt reporting of 
adverse drug reaction 
  
Prompt reporting of ARVs adverse 
drug reactions to National 









Key Informant Interview Results 
 
First, I asked the respondents questions about the overall functioning of the supply chain 
system (Appendix 4). In addition, I explored their views on barriers and facilitators for each of 
the major components of the supply chain system. Like the survey, the interview guide aligned 
with the research theoretical framework. Furthermore, the interview guide explored respondents’ 
opinions of the current state of the Nigeria HIV/AIDS supply chain system. I asked respondents 
to give insight on reasons for poor implementation of past recommendations to improve the 
supply chain system from prior studies. 
In general, the views of the respondents did not differ significantly by their geographic 
location or place of work in identifying the barriers and solutions to the address them. There 
were a few instances for stakeholder’s coordination in planning, quantification, and 
procurement, where federal and state level respondents identified unique perspectives on 
solutions to the identified challenges. Below are the results from the key informant interview 
under the major components identified for the research. 
 
Overall Assessment 
On the overall assessment of the Nigeria HIV/AIDS supply chain system, most of the 
respondents indicated that the system had evolved over time and had made significant 
improvements in the last decade. However, most of the respondents also noted that the system 
needed more improvements to enhance its efficiency. One respondent described the system 
thus: 
I think the pharmaceutical and laboratory supply chain for the HIV program in Nigeria 
has improved significantly over the last decade but I still believe that there is still a very 
large room for improvement especially in some components of the supply chain because 
I believe that currently the optimal benefit that can be derived from the supply chain 





This theme was consistent across most of the respondents. Furthermore, one 
respondent noted that the system as a whole was effective, but added a cautionary note, that 
the existing system may not be sustainable: “This is my overall assessment, it is an organized 
system, effective in doing what it is supposed to do, but it cannot be sustained by the recipient, 




On product selection, many respondents, both federal and state level, identified poor 
dissemination of national HIV/AIDS treatment guidelines to the clinics as a major barrier to the 
program. As a result, the health workers had limited knowledge and poorly implemented the 
guidelines. This had adversely affected the quality of services provided to patients accessing 
services at these clinics:  
In talking about challenges, I know in the past when there have been treatment 
guidelines being brought out. It usually ends of at the central level with big meetings and 
the guidelines are launched. Nobody has really asked how these are cascaded further 
down to service delivery points or any efforts made to see if those things are there or 
being used at the service delivery points.  
 
In addition, many federal level respondents noted poor documentation of adverse drug 
reactions and the failure of clinics to report incidents of adverse reactions to the authorities as 
another barrier: 
For example, I could remember when during the streamlining [i.e. new guideline revision] 
of the ARVs happened in 2012. Some people will say that they have not gotten the 
information on what is happening, hence we have such constraints. So, there is need to 
improve information dissemination system. Also, from the bottom up, the people working 
in the clinics [need] to report adverse drug reactions, because we cannot continue to rely 




We have so many patients having adverse drug reaction for example with Efavirenz. 
People often say it, but the question is whether it has been documented.  
 
Respondents also noted the problem of depending on donors for product selection, 
rather than basing product procurement on local preferences. This often happens because the 
donors fund the procurement of these products and hence guide product selection to align with 
the products they will finance. For example, one respondent noted: 
So, because the government funds are limited, they tend to lean more towards the 
donors for procurement and the donors usually have other interests that guides their 
product selection. So, you have a situation where the country basically is controlled by 
what the donors are bringing in. There is a standard product selection, most of what is 
done in the country relies more on what is in the World Health Organization guideline but 




Many respondents suggested prompt information dissemination of new HIV/AIDS 
treatment guidelines to the health workers at the clinics. Some state level respondents 
suggested electronic dissemination of the guidelines via e-mails to many of the health workers 
that now have access to smartphones and internet connection: 
In the area of effective communication of the guideline for me, [I] am looking at a 
situation where at the national level there is a database of the e-mail contacts of every 
stakeholder that is involved in HIV program in Nigeria so that when we have revisions, 
whether it is the algorithm or treatment guideline, this can be promptly circulated.  
[Regarding] our guideline dissemination. We could make e-copy of it. As long as it has 
been finalized, everyone should have a copy. We could ask government to make e-
copies and protect them so that nobody can change anything. Disseminate them widely. 
We are in an e-age. We do hard copies it is important, and they are sent, but that one or 
two copies might just be in one office, but with e-copy, many people have phones now, 





In addition, respondents suggested that government should create mechanisms to 
monitor and support reporting of adverse drug reactions and to use local data to inform product 
selection. Respondents further proposed building the capacity of health workers to use the new 
guidelines and to create systems to actively monitor the use of the guidelines. Excerpts from 
some of the respondents include: 
We need to implement the active search for patients with side effects. There was a form 
that was developed recently to have every ART client to report on any adverse effect at 
all that they are experiencing during every clinic visit. That has not been operationalized 
and it needs to be operationalized, so we can generate more local evidence…These will 
guide product selection.   
“Number one is to improve [increase] the human resource capacity at that level and if 
human resource capacity is improved [increased in number], then they will be better 
informed via training and retraining, the importance of data, logistics data, and clinical 
data will be used to take these decisions. 
 
 
Quantification and Procurement 
Barriers 
On quantification and procurement, many respondents noted that inaccurate data are 
used to guide procurement decisions. This leads to both under- and over-supply of different 
products. Inadequate quantities of certain types of products are purchased, leading to product 
unavailability at the clinics due to inaccurate data. On the other hand, excess supplies of other 
products are being purchased, leading to expiries. One respondent stated thus: “Data is key in 
quantification; it is one of the most important requirements in quantification. Getting the wrong 
data, you either quantify to overstock [via procurement above requirement] or procure 
commodities that would not serve the populace.”  
In addition, the respondents identified poor coordination of procurement plans and 
product requirements among the stakeholders (federal government, state governments, and 




these stakeholders. This is notable in coordination of the procurement plans between the 
federal and state governments. This is often the case as the State governments are 
independent of federal government, on health matters, and may decide not to take directive or 
collaborate with the federal government. Some respondents noted that sometimes the state 
governments’ commodity procurements are based on political reasons for popularity rather than 
technical product needs for service delivery. Some of the state level respondents identified the 
poor involvement of state governments in national quantification activities (organized by federal 
government and donors) as the cause of this poor coordination as noted by a respondent thus: 
“...most of the time, our quantification happens only at the national level without resource to the 
needs at the state level.” The poor involvement of the state governments results in duplication of 
efforts. This is because the State governments may decide to procure products not required, as 
the federal government and/or donors already procure the products, while needed products are 
not procured. The consequence is limitation on the number of patients that can benefit from 
available resources:  
Government does not share data with other stakeholders. Coordination is also an issue. 
If donor A is buying the same commodity that donor B is buying, they are likely going to 
buy the same quantity. So, coordination, inaccurate data and lack of government 
transparency are the issues in quantification where it affects procurement decisions. 
Donors may not know what to buy, they may over procure which will lead to expires at 
the end. That way, if you are supposed to use the funding to treat, say 500 patients, you 




To address the barriers, many respondents highlighted the need to collect and validate 
data from all the healthcare levels in the system. This is to ensure accurate data is used to 
inform quantification and procurement decisions: 
“So, I feel we need to exhaust and explore the opportunities of getting data from all the 
levels of government and all the levels of [health] care and making sure that such data 





Other respondents spoke about the need to build the capacity of the health workers to 
ensure accurate and timely data generation: 
The system to [be] put in place is one [thing], the ability to be able to build the capacity of 
staff to be able to report quality data [is another thing]. I think that over time and with 
experience, on the job training remains the best to be able to do that.  
 
 
In addition, many respondents recommended coordination of procurement plans among 
the various actors involved in the quantification and procurement processes (federal and state 
governments, and donors). They suggested that this could be achieved through transparent and 
prompt information sharing among the various stakeholders. Furthermore, state level 
respondents proposed that the involvement of the state governments in the national 
quantification activities would help ensure the state governments were aware of federal 
procurement decisions to minimize duplication of efforts in procurement: 
Government needs to come out and be transparent in their procurement process. 
Coordinate with donors, let the donors know what government is procuring. Donors 
needs to be transparent as well so we are not blaming only government. I know the 
system used to be [in] silos with everyone buying on their own but it has now improved 
[amongst donors] with pooled procurement…which has helped in reducing expiries we 
noticed in the past. So, coordination, transparency, motivation of people that generate 
this data that we use to quantify for procurement [is very vital].   
 
I also think that it is also very important that state governments are involved when 
national quantification is being done even though they may not play a major role in the 
supply of data or in the actual process but we can also have opportunities for 
dissemination of these quantification output in a timely manner so that whenever any 
state decides to buy, whatever [they] buy [can be] virtually incorporated into the national 
pool and they will not be able to go outside what has been agreed at the national level. I 








Warehousing and Distribution 
Barriers 
Many respondents noted that there was a lack of both the warehousing infrastructure, 
and trained workers with the capacity to manage the existing warehouses. A respondent 
reported this challenge thus: “…the main constraint to warehousing in Nigeria [availability of] 
quality pharma-grade warehousing. A lot of the state warehouses are basically just storage 
facilities. So, that is a major constraint, [poor] infrastructure.” This resulted in product expiration 
at the warehouses as good warehousing standard operating procedures were not followed in 
managing health products. Some noted these barriers as follows: 
[Poor capacity of the personnel] that is the bane of the warehousing system. What 
amount of training do we put into the personnel that manage our warehouses? You 
cannot run away from the quality of the personnel [as] that determines the quality of the 
work. We have people who often are not trained in the act of warehousing and 
commodity storage and when it comes to that a lot of issues [it goes] to back to training.  
[During visit to a warehouse] the stock was not arranged, and they were not even 
observing the principles of first-to-expire, first-out. In trying to help them rearrange the 
store, you find out a lot of commodities have expired, and they are not aware the 
commodities are there. Inadequate storage practices in the health system is also a 
concern for warehousing and distribution.  
 
Furthermore, many state level respondents identified the late delivery of health products, 
delivery to the wrong locations and inappropriate distribution practices through untrained proxies 
(i.e. persons not part of the supply system), and delivery at odd hours to the clinics by the third-
party logistics service providers (3PLs), as barriers. Many of state level respondents noted that 
these inappropriate distribution practices had continued despite complaints raised previously by 
the health workers to implementing partners managing the 3PLs. This they opined was as result 
of poor monitoring and implementation of contractual terms, (especially concerning penalty 




I think the problem has to do with distribution because the courier agents (3PL) that are 
used to deliver this product end up not delivering this product to the service deliver point. 
We have heard stories where some of the courier agents hand over the products to third 
party or fourth party agents [intermediaries] for onward delivery.  
On the distribution side, poor monitoring of courier services [is a barrier]; have we 
punished courier service providers for late deliveries? What did we put in our contract 
while having these services with these providers? What are the penalties for late 
deliveries? If there are penalties for every late delivery by deducting certain percentage 
of money during payment, they will sit up.  
 
Solutions 
To address the identified barriers on warehousing system, some respondents 
recommended that government upgrade available warehouses to pharmaceutical-grade 
standards and engaging the private sector to manage these warehouses as noted by a 
respondent: if the government can, working with donors, provide [more] pharmaceutical grade 
warehouses and even if they can’t, they may consider engaging private pharmaceutical 
warehouses for storage of these commodities”. In addition, government should establish and 
maintain minimum standards for warehousing operations. This should include capacity building 
of personnel that operate the warehouses. Also, respondents recommended funding to maintain 
the infrastructure and support needed upgrades: 
In terms of warehouse, the minimum criteria for a warehouse should be met. Now for the 
warehouse personnel…[they] should be trained on minimum criteria for a pharma-grade 
warehouse. Two, monitoring; monitoring to ensure compliance with minimum 
requirements. Three, funding; meeting minimum requirements will also require funding. 
Funding in term[s] of maintenance of infrastructure. It may not be so much but if the 
funding is being budgeted for and is ensured that it is being used for such purposes too, 
that will bring about an improvement. 
 
On distribution of commodities, some of the respondents recommended strict 
enforcement of the distribution contract agreements as a strategy to close the performance 
gaps of the third-party logistics providers (3PLs). This can be achieved through real-time 




responsibility for monitoring. The state level respondents proposed the engagement of the state 
officials, who are closer to the clinics, in monitoring the activities of the 3PLs to address the 
problem of inappropriate deliveries. Other respondents recommended creating opportunities for 
competition among the private distribution agents as a performance management strategy that 
will continue to spur the third parties to meet their contractual agreements: 
Most organizations that are responsible for distribution go into partnership with their 
distribution vendors. There are contracts with stipulations at what time commodities 
should be distributed. I think those organizations should go back and see how they can 
enforce the stipulations of those contracts so that incidents of late deliveries can be 
brought down to the minimum.  
It is the engagement of a third-party logistics agent; the agreement needs to be reviewed 
to ensure that they are able to deliver these product[s] to the service delivery point 
directly by themselves without using any middle agent that can delay the process of 
delivery. Also, the items should be delivered directly to the contact person.  
 
In addition, one of the respondents noted the importance of collecting real-time data 
about when the deliveries are made to the facility: 
 
In the area of late deliveries, I think we need to put in place opportunities for real-time 
reporting of date and time when deliveries are made to the facilities. This will ensure that 
when facilities receive their commodities, they can quickly put in SMS [short message 
service] or something that will quickly inform people at the federal level that are 
monitoring this distribution. Another thing that can also help is to see how the state level 
actors can also be involved in the monitoring of the distribution of commodities…I also 
think that the national program needs to create competition among these distribution 
agents that are currently being used. 
 
 
Logistics Management Information System 
Barriers 
Many respondents highlighted poor record keeping practices in the clinics as problems 
for the logistics management information system (LMIS). This occurs because record keeping 




data collection, which is the current practice, is very laborious. Furthermore, when the tools are 
available, they are not user-friendly (i.e. bulky). This makes it difficult for the health worker to 
accurately complete them on time. The consequence of this is the poor quality of data submitted 
for decision-making, which disrupts health services delivery:  
Yes, I agree that unavailability of tools and poor recording-keeping are major barriers in 
the supply chain and I think that this is because most of the tools that are currently being 
used in these facilities are outdated…. Also, these facilities also lack the infrastructural 
support to have electronic management system. I think these are some of the issues we 
have at these facilities.  
I will say the manual system is a problem. We do a lot of manual system [processes], 
from drug dispensing to inputting the data at the end of the day. These are manual 
system and then the transmission of the report, you still have to look for [computer] 
system to type it in, then send it to the state LMCU…Even at the national level there are 
still errors that come up, transcription errors. Manual process is a problem.  
 
In addition, many respondents noted the limited human capacity (both in numbers and 
skills) to keep records of supply chain transactions in the clinics as another barrier. The attrition 
of skilled manpower from government services worsens the situation. The attrition is as result of 
poor remuneration and unconducive work environment that is a systemic issue for the entire 
health system beyond health supply chain. As noted by a respondent “…we are living in a 
country where people work for months without being paid…So, poor motivation of our 
government staff is a key challenge.”. This will require an overall health system intervention 
beyond supply chain management system.  
Other feedback from a respondent on cause of the human resource gap in the system 
include: 
Also, we have also observed that there [are] frequent changes in the responsible 
personnel at facilities. So even after we have worked with implementing partners to train 
the service providers who are managing the [product] supplies at the facilities, we 
usually have frequent redeployment of personnel and so this creates capacity gaps in 
the personnel at the facilities and some of them when they join the program they are not 






For the barriers identified, many of the respondents proposed the use of technology in 
the management of supply chain data. This will alleviate the burden of data management for the 
health workers at the clinics and minimize errors in data transmission. Furthermore, many 
respondents proposed investment by government in the infrastructure (computers, internet 
connection) for data management and transmission, and use of mobile technology as strategies 
to implement this recommendation. Examples of the recommendations from respondents 
include: 
We [the government] need to invest in some of these infrastructure[s], internet, 
computers and train people to use those things because those system seems to be 
faster because you will be able to transmit reports faster and ultimately you have less 
people and less paper work to do. Also, if we don’t have computers, can we look at the 
popular handsets [mobile phone], the androids, [and] the popular phones that everybody 
is using for now, [that] can we consider that as a means of generating report.   
For the issue of the poor recording-keeping and use of tools, I think we should start 
thinking about developing and supporting them with electronic system. I believe this 
would minimize the burden of filling many of these forms and worksheets especially 
during dispensing and preparation of LMIS reports. We should also be looking at a 
mobile-based LMIS system which is based on something like SMS rather than internet-
based [system] because I know that a number of health facilities even in Lagos where 
you think is far more developed than others, you still have challenge of internet access.  
 
In addition, many respondents identified cost-effective and targeted capacity building of 
health workers via training on required skills, followed with mentoring and supportive 
supervision on supply chain data management and use, as strategies to address challenges of 
LMIS. Respondents further recommended behavioral change management via education and 
performance-based incentives. These they noted will enable the health workers to imbibe the 
culture of documentation. In addition, performance-based incentives will motivate the health 
workers take ownership data management processes and data use for decision-making. 




I think we should start developing training curriculum that target the essential needs of 
the facilities in keeping records and generating reports. This will help us minimize the 
time required for some of these capacity building and the cost which has always been 
the limitation around continuous capacity building.  
 
….one way I heard people talk about [this], not in the HIV space, but in other health 
supply chain space is to build a performance-based incentive system that will motivate 
proper documentation and proper record keeping and timely transmission of records. 
Also, the idea of exploring the game theory where something like competition is created 
among peers as to who are the people that will get the most accurate data in the best 
possible time. 
  
Serving the Client 
Barriers 
Many respondents noted that the primary barrier in delivering services to the clients was 
the unavailability of health products in the clinics. As respondent noted, “two major issues 
include [un]availability of products and [poor] remuneration of staff. Unavailability of products 
affects serving the clients for over 90%. If a client is there and there is no product, then there is 
no program.” Respondents suggested that this was primarily due to the inaccurate logistics data 
management and poor work attitudes. These are often linked to low staff morale as result of 
poor remuneration, unconducive working environments, and inadequate human resources 
capacity to provide services. The consequences of these include health services disruption, 
patient dissatisfaction, and loss to follow up in the chronic treatment of HIV positive clients: 
The major constraint is personnel attitude. The personnel or the healthcare worker that 
attend to the clients, their attitude is key and if their attitude is not welcoming then the 
client will not feel so free to have an expressive discussion with respect to their health. 
Another major constraint is inconvenience of the facility. If…there is no secluded 
comfortable environment to have meaningful patient counseling and discussion. Another 
constraint, poor logistics [data], stock out will be an issue [with inaccurate logistic data]. 
And if there is stock out due to poor logistic data, then they will be unable to serve all the 
clients [at] that service delivery point. Product unavailability? It is a major factor because 







Some of the respondents recommended the deployment of adequate human resources 
that are well trained and mentored on HIV/AIDS supply chain service delivery. The capacity 
building, they opined will enable the health workers to understand the impact of HIV/AIDS 
service disruption. It will also serve as an incentive to motivate performance on positive attitude 
to the clients and correct supply chain documentation. These the respondents suggested will 
improve the availability of health products at the clinics for service delivery since these products 
are available at the central warehouses in Nigeria: 
For the remuneration of staff, I will want to think that trying to give a small incentive like a 
little form of training, even if it is onsite training with a certificate that will help the staff so 
they know they have an added knowledge. 
 
Leadership and System Support 
Barriers 
Many respondents identified inadequate government funding, and weak leadership 
systems as barriers for the HIV/AIDS supply chain system. These result in limited supervisory 
and accountability monitoring because of poor government commitment to the HIV/AIDS supply 
chain system. Furthermore, many respondents suggested that limited capacity of the 
government personnel at the logistics management coordinating units (LMCU) to provide the 
required leadership had resulted in significant dependence on donor organizations to provide 
leadership and system support for the system: 
I think for me, leadership and system support is also one of the weakest link in the HIV 
program supply chain and it is like a cycle because if don’t have adequate funding, then 
you do not have the required funds for you to be able to provide monitoring and 
supervision, you do not have the funding to be able to employ more people. I think the 
LMCU cannot provide the leadership and system support, if there is no opportunity to 






Many respondents recommended high-level engagement with senior government 
officials, with authorities to make decisions, by the donors and private organizations supporting 
HIV/AIDS supply chain as a solution. Donor organizations can advocate with senior leaders on 
proper funding allocations and disbursement for supply chain activities. The senior government 
officials should also be encouraged to demand accountability of the deployed resources from 
the donors and government technical officers charged with the responsibility of supporting the 
HIV/AIDS supply chain. Furthermore, some respondents proposed capacity building of the 
government staff on resources accountability, monitoring of work plan implementation and 
reporting to the senior leadership as solutions: 
The advocacy just goes beyond the Minister [for Health]. It needs to go all the way up to 
the presidency to enable him [to] understand why he needs to invest in health and invest 
in public health specifically. It is something that needs to go beyond the state 
government and up to federal government. Until that happens, even if you go to the 
state, they could create LMCU, [if] there are no funds to support the activities [they 
cannot make progress]. Right now, most of them are waiting for the donors to support 
activities that happen at the state level and that is not sustainable. 
 
 
Other Environmental Factors 
Some respondents highlighted other factors that affect HIV/AIDS supply chain.  This 
includes fear and insecurity in the community that impedes health product distribution. Some 
respondents also noted the limited involvement of the patients in the HIV/AIDS supply as 
another factor that impairs the efficacy of HIV/AIDS products. This can be addressed by 
educating the patients on how to store their medications at home and report on medication 





One of the neglected areas of supply chain happens to be involving the patient. Making 
the patients play an active role on their therapy. Getting feedback from the patients on 
this drug [they] are taking. That is something that needs to be included in the supply 
chain going forward.  
One other essential factor that I think is the angle of the patients…the patients have a lot 
of responsibility. For example, a patient comes to a facility, he is given product that we 
had stored very efficiently. That patient should know that if I take this product home, I 
should also see that there is an aspect of storage I can do at home [to maintain 
therapeutic efficacy of the product]. 
 
Implementation Challenges 
Based on feedback from some respondents, the failure to implement some of earlier 
recommendations was because the relevant government authorities did not fully understand 
and accept the initiatives before they were made public by the supporting organizations. This 
happens because the implementing partners are sometimes eager to release results of their 
researches to align with mandate given to them by the donors. Unfortunately, government is not 
in a hurry to make significant changes in the system as result of the long-term impact and 
financial implications of those decisions. In addition, respondents suggested the involvement of 
the government in developing the final recommendations and any plan needed to implement the 
recommendations. Government involvement can help ensure that the proposals are 
implementable considering local constraints.  
In addition to the involvement in drafting recommendations, some respondents thought 
that government needed to be at the forefront of the implementation efforts. For example, a 
respondent suggested that procurement across private and governmental funding could be 
more efficient if the efforts were coordinated (harmonized) under governmental leadership. The 
respondents also suggested that the internal acceptance of the new ideas would enable the 
right government authority to issue directives that will support implementation. The issuance of 
implementation directives by the ‘right’ government institution is essential because not all the 




Respondents thought that part of the reason for the past failure was the lack of an 
oversight structure to ensure that the recommended changes were implemented. Several 
respondents proposed putting mechanisms in place for regular review of the agreed 
implementation plans along with clear key performance measures.  Assigning responsible 
persons within government agencies and holding them accountable through peer review 
sessions were other strategies to promote implementation of the new ideas.   
Other respondents noted the lack of governmental funding at the state and federal levels 
hampered prior efforts at SCM improvement. Respondents recommended that the donors 
encourage government investments to implement these recommendations through peer reviews 
among different state governments and donors. This may be further supported through 
incentivizing performance through incremental performance-based financing from the donors. 
The use of performance-based financing (i.e. setting up target(s) that states would need to meet 
to obtain project funding) will encourage the state governments to meet agreed milestones for 
program implementation.  
In addition, respondents noted lack of trained workers needed to implement prior 
recommendations. They recommended building the capacity of the workforce on expected level 
of performance. This is vital, as performance expectation on new recommendations are 
sometimes not achieved because those saddled with the responsibility may not have the 
required capacity to implement the new recommendations. For example, recommendations to 
implement electronic-based data collection system may fail in locations where relevant 
personnel do not have access to electronic tools or do not have the skill to use available tools:  
One thing has been the issue of ego. You know HIV/AIDS is such that government 
cannot do it alone, you need the support of partners. In Nigeria when it is partners that 
are driving a particular strategy, the government feel reluctant because they are not 
taking the lead. One thing I advise is that when the improvement idea is coming from the 
donor, let the government buy-in before it is made public. Right from the planning stage, 




from them [government], let them [government] be at the forefront in the implementation. 
When it happens that way, then there will be success. 
For these new recommendations to be effectively utilized, there is need to develop a 
workable work plan…For each activity in the work plan, there is need to have a key 
person that is responsible for its implementation…I also want to suggest that where 
possible, we should also be able to commend or motivate those that were able to meet 





Table 6 include the summary of the key informant interview responses grouped by the 
theme based on the theoretical construct of the research. The summary identified barriers and 
solutions provided by the respondents for an effective and efficient HIV/AIDS pharmaceutical 
and laboratory supply chain management system in Nigeria. The themes have been grouped 
under the theoretical construct for the research and they revolve around similar themes as 














Table 6: Summary of Key Informant Interview Response 







Poor dissemination of guidelines Prompt information dissemination on guidelines 
Limited knowledge on guidelines Electronic dissemination of guidelines 
Poor implementation of guidelines Systems to monitor adverse drug reaction 
Poor documentation of adverse drug 
reactions 
Capacity-building of health workers on 
guidelines 
Donor dependence for product selection  








Inaccurate data for procurement decisions Collection and validation of data from clinics 
Over or under supply of product 
requirements Capacity-building of health workers 
Poor coordination of procurement 
requirements 
Coordination of procurement plan among 
stakeholders 
Poor visibility into procurement plans 
Involvement of state governments in 
quantification 
Limited involvement of States in 
quantification   











Inadequate warehousing infrastructure 
Government upgrade of warehouse 
infrastructure 
Inadequate human capacity to manage 
warehouses 
Engagement of private sector in warehouse 
management 
Expiration of products 
Establishment of minimum warehousing 
standards 
Late delivery of health products Capacity-building of warehouse operators 
Delivery to inappropriate locations Funding to maintain warehousing infrastructure 
Poor monitoring of 3PLs contract terms Enforcement of 3PLs contract terms 
  Real-time monitoring of distribution services 
  Increase competition among 3PLs 










Poor record keeping practices 
Deployment of technology to improve data 
management 
Unavailability record keeping tools Government investment in data infrastructure 
Laborious manual data management system Use of mobile technology for data collection 
Bulky data collection tools Cost-effective and targeted capacity-building 
Limited human resources capacity Behavioral change management 
Attrition of skilled staff Performance-based incentives 








Unavailability of health products at the clinics Improve availability of health products at clinics 
Inaccurate logistics data 
Deployment of adequate skilled human 
resources 
Poor staff work attitude Capacity-building of staff 
Poor staff remuneration    
Unconducive work environment   
Inadequate human resources capacity   







Inadequate government funding 
High-level engagement with senior government 
officials 
Weak government leadership 
Advocacy with senior leaders on adequate 
funding 
Limited supervisory and accountability 
system 
Demand for accountability of deployed 
resources 





Recommended Policy Changes  
Many of the respondents noted that the current policy framework was adequate to 
support implementation of HIV/AIDS supply chain in Nigeria. The major gaps were the lack of 
political will, limited coordination, and funding for the implementation of the policy provisions. 
However, a few of the respondents recommended policy changes to improve the likelihood of 
policy implementation and impact. For example, some respondents recommended active 
involvement of the private sector in managing the public health supply chain. This was proposed 
as a strategy to promote efficiency and accountability in use of resources in the system. In 
addition, some respondents recommended inclusion of a clear policy statement on how much 
funding the government should contribute to support public health supply chain: “There is a 
need to adjust the current the policy and guidelines for HIV supply chain management so that 
the role of government in spending more of their money is emphasized.” Policy statements do 
not have the force of law; however, it serves as guiding principles on the activities of 
government and that of partners working with the government. Furthermore, it forms the 
foundation for future legislation after several years of policy implementation. 
Others suggested that government establish standards on the minimum remaining shelf 
life of product (i.e. length of time to expiry) before it can be imported into the country. Several 
respondents further suggested decentralizing the warehousing infrastructure, using more than 
the single warehouse used in current policy. Also, a few respondents recommended 
harmonizing the distribution frequencies (across health products). In addition, the respondent 
noted the need for guidelines for how long it should take to distribute products in each 
distribution cycle (i.e. all ARVs and RTKs should be distributed within three weeks of report 
submission from the clinics). Finally, some respondents proposed the development of a policy 
implementation plan, to ensure that existing or future iteration of the policies are implemented.  




reporting on health supply chain activities included in the policy. These are important changes 
considering the dynamic changes in the HIV/AIDS program implementation with innovations in 
treatment regimen and need to scale up services. Examples of comments from respondents 
include:    
Considering that there a lot of changes that are happening in the HIV world, I think the 
policy and the guidelines needs to be reviewed, to meet emerging challenges. So, I think 
we [government] need to spend more resources in terms of funding, in terms of time to 
monitor the system to improve the coordination and implementation of these policies and 
guidelines. 
I think government needs to sit down with all stakeholders and draft clear policies on 
supply chain management. And government needs to separate the private sector from 
public sector. The current policy on supply chain management looks at operating mega 
distribution centers, which for me is for private sectors. We need to have public sector 
policies that stipulates, what is the shelf life of the pharmaceuticals that are coming into 
the country, what kind of warehouse do we need to use? What is the distribution cycle 




Many respondents identified that increased government leadership and additional 
funding of the supply chain system as priority recommendations to improve the HIV/AIDS supply 
chain system. This will require active engagement of senior government leaders and 
engagement with other stakeholders with resources that can influence government decisions at 
the highest level. Supporting the management of accurate supply chain data and improving data 
visibility to inform government decisions and investments were other priority recommendations 
suggested by other respondents: 
Top priority should be around funding, governance and support, leadership and support 
and our LMIS. The reason I say this is because, leadership and support is key in making 
sure that every other thing works. If we do the LMIS correctly, it will inform every other 
thing. 
Ensuring that data generated from health facilities is of good quality and can inform 
decision making. Not just having good quality data but also ensuring it comes on time to 





CHAPTER 5: DISCUSSIONS AND RECOMMENDATIONS 
 
This chapter reviews the major themes that emerged from the research. In addition, I 
have included preliminary recommendations that can help improve the HIV/AIDs SCM system. 
As discussed further in the Plan for Change, I will be working with governmental officials to get 




In general, the study was designed to discover the barriers and solutions to an efficient 
and effective supply chain management for the HIV/AIDS program in Nigeria. To identify the 
specific challenges facing each product type (i.e. antiretroviral drugs and HIV rapid test kits), the 
survey was divided into two parts to address specifics for ARVs and RTKs. It was not surprising 
that respondents working within the RTKs SCM reported more challenges compared to those 
working with the ARVs SCM system. This is because the ARVs SCM system had received more 
attention over the years. This had been the case especially on data accuracy, data submission 
timeliness, and capacity building for health workers. In addition, laboratory products (RTKs 
being one of them) are more challenging to manage because of the special handling (i.e. 
temperature monitoring, different pack sizes and utilization protocols) and reporting 
requirements (i.e. reported in different units of measure) when compared with ARVs. For 
example, on RTKs poor record keeping received a 100% score as an “important” or “very 
important” barrier. This highlights how this barrier had significantly affected the RTKs SCM. 




the RTKs supply chain while poor reporting on adverse drug reaction is unique to ARVs supply 
chain. These further buttresses the inadequate communication channels between the health 
workers and the national regulatory authorities. The summary of the barriers revolves around 
poor logistics data management and use, inadequate leadership and funding, limited human 
resource capacity and performance management, weak stakeholders’ coordination and 
disruption in service delivery. 
The solutions proposed by respondents for both RTKs and ARVs were significantly 
aligned. These common proposed solutions are already reflected in the Government’s efforts to 
integrate the RTKs and ARVs supply chain systems in order to close gaps faced by both 
systems. Both RTKs and ARVs products are stored in the same warehouses and distributed to 
the clinics using the same vehicles. The data collection forms for ARVs and RTKs are being 
harmonized and submitted at the same time to the state government from the health facilities. 
This mechanism was put in place to improve data accuracy through facility-level peer-review 
between different health workers generating these reports. In summary the solutions to address 
identified barriers falls within the themes of strengthening stakeholders’ coordination of the 
supply chain system, improving supply chain data management and use for decision making, 
improving human resources and performance management, government leadership and funding 
support, and improvement in quality of service delivery at the clinics. 
Below are details of the overall emerging themes for the HIV/AIDS supply chain system 
and recommendations to improve the system.       
 
1. Stakeholder Coordination and Information Dissemination 
The limited coordination and information dissemination among the various 




for the HIV/AIDS supply chain. The coordination challenges were highlighted in quantification 
and procurement of HIV/AIDS products. In addition, poor information dissemination to the clinics 
from the federal and state governments—especially on new service delivery guidelines for 
ARVs and quality control protocols of RTKs—were other major gaps in the SCM system. Spicer 
et al. (2010) documented challenges across seven countries with national and subnational 
government’s coordination framework in global health programs.  Spicer noted this was a factor 
that needs to be addressed to improve health program impact. Chima and Homedes (2015) 
further reiterated the need for robust coordination systems within global health programs in 
Nigeria to ensure that available resources are optimally used to make desired health impacts.     
In Nigeria, the State governments are independent of the Federal government on health-
related matters and have the choice of whether to align with the federal government’s plans and 
decisions. This is because of the lack of clarity in the Nigeria policy and legal framework on the 
tier of government that controls health services. This gives the State governments autonomy on 
health issues, but it creates room for duplication of efforts if plans are not aligned between the 
federal and state governments. While there had been good effort in planning and coordination 
among the stakeholders at the national level (i.e. between donors and federal government), the 
state officials had not been actively involved in the in planning and coordination for HIV/AIDS 
commodity procurement and management. For example, some of the state level respondents 
noted that the state government officials are often not part of the national efforts to quantify 
needs for HIV/AIDS commodities. The limited involvement of state officials and coordination 
with the federal government results in duplication of efforts by the various stakeholders (when 
the state decides to independently procure HIV/AIDS commodities) resulting in suboptimal use 
of available resources for commodity procurement. This happens because some state 
governments (not all) are unwilling to coordinate among themselves or request information from 




federal and state governments are from opposing political parties. The suboptimal utilization of 
national resources (i.e. pooling federal and state government funds) highlights the need for the 
federal government to advocate with state governments to invest available resources in filling 
commodity procurement gaps.  
Some of the national respondents stated that there was limited federal engagement with 
the states because the state governments were not clear on whether they would commit funds 
for HIV/AIDS commodity procurement. Some thought that some state governments purchase 
products that generate public attention, for political reasons, rather than bridging the commodity 
gaps in the system for service delivery. The narrative aligns with the trend for the other health 
programs as well. This happens as health is seen as a social intervention and used for political 
campaigns that will endear governments to the people.  
Another problem is the slow pace of the government decision-making process at both 
federal and state governments. This slows information dissemination to the clinics. Hence, 
information that may be available is not shared with the clinics until it receives official 
government endorsement, which creates significant gaps in the system over an extended 
period.  
Recommendation #1.1. Donors and private sector organizations should engage directly 
with federal and state governments to support coordination and collaboration among the 
different stakeholders in the system to harmonize commodity procurement plans.  
  
The donors and private organizations supporting the HIV/AIDS SCM system should 
engage directly with both the senior and technical officers within the federal and state 
governments to facilitate harmonization of HIV/AIDS products procurement plans and funding 
gaps among stakeholders. While this is not a sustainable strategy for supporting the HIV/AIDS 
SCM system, it will serve as a catalyst to bring together the federal and state governments to 
achieve a common goal of health service delivery and promote government ownership of the 




the technical officers, at the logistics management coordinating unit (LMCU), and the senior 
government officials, with decision-making authority, that can make the required changes in the 
system in funding the system. This is a useful strategy as the donors and private organizations 
often enjoy the trust of the senior government officials based on their track record of 
performance in support of the health system. The regular partner’s forum established in some 
state for engagement between donors and senior government officials can be used close the 
communication gaps. Finally, pooling of resources for commodity procurement will enable 
government to leverage economies of scale and reduce cost of health product procurement 
(Larson, Burn, Minnick-Sakal, O’Keefe Douglas, & Kuritsky, 2014). 
 
Recommendation #1.2. Government officials should facilitate prompt dissemination of 
changes in the national HIV/AIDS treatment guidelines and SCM system using 
appropriate circulars via electronic systems. 
 
Wide dissemination of information on the new guidelines will be a useful strategy to 
improve the health supply chain system. Often senior government leaders with authority to act 
on new recommendations are not aware of the new information or have not received the 
recommendations in the necessary format needed before they can act. Improving information 
dissemination through development of a dissemination plan that is followed with short and 
simple publications for target audiences will be ideal (Schipper, Bakker, De Wit, Ket & Abma, 
2016). In addition, sharing the information widely through e-mail listserv and following up with 
formal communication of these recommendations to senior government leaders by the technical 
officers will be helpful. For instance, the national HIV/AIDS treatment guidelines should be 
disseminated electronically via e-mails and be available on official government websites for 
download as an official government document for referencing. This will also enable health 
workers and leaders to continue to work with existing information while having channels to 




approaches should be adopted when there are changes in the HIV/AIDS supply chain system to 
promote prompt information dissemination and use at the states and health facilities.  
 
2. Leadership, Funding, and Accountability  
Inadequate funding provided by the federal and state governments in support of the 
HIV/AIDS supply chain management system has resulted in significant dependence on donors 
to meet the needs of the public health system (Chima & Homedes, 2015). The consequence of 
this limited funding is inadequate leadership at the federal level to drive the process of HIV/AIDS 
supply chain improvement. While the system had improved significantly in the last decade and 
is providing HIV/AIDS commodities to the patients consistently, it is largely dependent on the 
leadership and external resources provided by donors. This may make the system 
unsustainable in the long-term especially with dwindling donor resources as result of global 
donor fatigue (Grepin, 2012). For example, one respondent noted that while the supply chain 
system was currently performing as designed, the federal and state governments due to limited 
governmental budget allocation to the health sector might not sustain it. Part of the reason for 
the inadequate governmental funding is competing priorities. The situation arises as the federal 
and state governments have other priority interventions (e.g. security, agriculture, publicity for 
public campaigns, etc.) in which they prefer to invest limited government resources. This also 
happens as government leaders often view the health sector as consumer of funds and do not 
relate the health of the people to overall productivity of the workforce. The different priorities of 
the senior government leaders limit the ability of the frontline workers to provide required 
leadership to the HIV/AIDS SCM system. In addition, senior governmental leaders (especially at 
the state level) do not give the same level of attention to the HIV/AIDS supply system to ensure 
proper management of funds as they do to other priority interventions where they have invested 




Recommendation #2.1. Government should budget adequate funds to provide leadership 
and implement improvements in the HIV/AIDS SCM system. 
 
The government needs to budget adequate funds during the annual budgeting cycle in 
order to improve the current HIV/AIDS SCM system. This is needed to enable the frontline 
workers in government to provide leadership in program implementation. This may include 
coordination meetings with donors and private sector organizations or monitoring SCM system 
implementation at the clinics. The federal government and many state governments use an 
envelope budgeting system. In this system, funds are allocated to different sectors of 
government with a defined ceiling amount irrespective of their need. For example, in the 2018 
federal government budget, the health sector was allocated N340.46 billion (~$945 million) 
which is about 4% of the federal budget as against national target of 15% (Onigbinde et al., 
2018). This figure was artificially determined based on government’s projected revenues—not 
based on actual health needs. The leaders within the thematic areas are expected to work 
within the budget ceiling. Even after the budget is set, government officials do not always 
release all the funds. Hence, donor and private sector organizations need to help support 
government technical officers in advocating for funding with the executive and legislative arms 
of government.   
Recommendation #2.2. Government should disburse budgeted governmental funding for 
HIV/AIDS SCM program implementation on a timely basis to support service delivery. 
 
Timely disbursement of needed funding that had been approved in the budget may be 
one of the most challenging problems for the program. Sometimes, the funds are not released 
for the entire budget cycle. Unavailability of projected state government revenues is often the 
cause of this delay. If revenues are not sufficient to cover the full budget for all government-
funded programs, then the national or state government may allocate limited resources based 




addition, if the funds were not released on time, they will be left unspent due to long 
bureaucratic approval processes. The unspent funds are returned to the government treasury at 
end of the budget cycle without a guarantee of receiving the funds in the next cycle. Advocacy 
by donors and private sector organizations is needed to encourage government officials to issue 
an official circular and timely release funds to support HIV/AIDS SCM system. Also, reporting 
systems should be put in place that enable the government technical officers to report to the 
senior government leaders, donors and private organization how disbursed funds had been 
utilized and the results achieved. The reporting system will encourage private organizations and 
donors to further lobby senior government leaders and legislators for more resource allocation 
via the envelope budgeting system.    
To mobilize funding from donors and local private organizations in support of the health 
supply chain system, there should a memorandum of understanding (MoU) between donors, 
private organizations, and government. The MoU will serve as incentives for state governments 
to coordinate funds and other resources from external sources and government that are needed 
for supply chain implementation. Part of the conditions in the MoU will include disbursement of 
government budgeted funds for program implementation to guarantee continue support from 
donors. This has been successfully implemented with the immunization and family planning 
programs in Nigeria--with funding from Nigeria-based foundations, governments, and 
international partners used to support the supply chain. While the MoU puts leadership and 
accountability on shoulders of government, it enables the private organizations to monitor the 
disbursements and utilization of government funds in addition to the funds from these 
organizations. The use of MoU to encourage government disbursement of appropriated funds is 
a model the HIV/AIDS program can copy from the other health programs in Nigeria. This may 






Recommendation #2.3. The government should strengthen accountability and 
management structures for the HIV/AIDS SCM system. 
 
Senior government officials should require progress updates on activities of the 
NPSCMP and LMCUs based on the approved annual work plan and budgetary disbursements. 
This is essential to ensure that deployed human and financial resources are effectively utilized 
for program implementation. The development and monitoring of annual performance metrics 
will enable senior government official observe progress on program implementation.  Constant 
reporting and oversight, along with consequences for failures, can incentivize positive 
behaviors. The offices of the Auditor General and Accountant General at both the federal and 
state governments should be used to monitor financial resource utilization and reporting.  
Furthermore, training the NPSCMP and LMCU staff on leadership and supervisory techniques 
can help them provide the requisite support to health workers at the clinics and demand 
accountability from the private sector and donors providing support to the system.   
 
3. Human Resources and Performance Management 
Inadequate human resources and poorly trained staff are also barriers to the system. 
Government has had problems attracting highly skilled workers, and those who are employed 
sometimes leave within a short period due to poor working conditions. This staff attrition results 
in an increased workload for remaining staff without adequate manpower to keep up with the 
required volume of needed services. This leads to poor customer service to the patients and in 
the performance of assigned tasks. Inadequate human resource capacity affects different 
components of the supply chain including data management, warehousing and distribution, 
service delivery and leadership systems. Furthermore, some of the staff from the implementing 
partners that provide warehousing and distribution services are also not well trained to manage 




challenge emanates from the personal relationships between these staff and the service 
providers. This limits their capability to hold these third-party logistics providers (3PLs) 
accountable for poor performances in service delivery. Hence, government and public staff who 
identify poor performance of third party vendors often discuss the problems verbally, rather than 
monitoring, documenting, and using the data to hold the private sector service providers 
accountable. The consequence of this is reoccurring problems of suboptimal performance from 
some of the private sector service providers on warehousing and distribution services. 
Recommendation #3.1. Government and private sector organizations should develop a 
targeted workforce development strategy to improve supply chain performance. 
 
Three mutually reinforcing strategies are needed to ensure an adequate supply of well-
trained staff needed for an efficient and effective HIV/AIDS SCM system. First, government 
must hire sufficient numbers of workers. This necessitates a formal workforce analysis to 
determine how many workers are needed and in what roles and locations. Second, government 
must employ new strategies for staff retention through performance-based career promotions, 
and time provided with encouragement that staff take vacation for rest and recuperation. These 
are some of the strategies used in the private sector to keep high performing staff even amid 
poor financial incentives due to budget constraints. Third, staff training should be targeted to the 
skills needed by each staff to perform assigned tasks. This will involve developing a strategic 
plan for human resources management for health supply chain management system (Trap, 
Musoke, Kirunda, Oteba, Embrey & Ross-Degnan, 2018). 
Significant resources have been spent in the past training of health workers on skills 
they did not put to use immediately which are often forgotten after many months of non-use. For 
example, training a health worker at the clinic who mostly collates logistics data, on 
management of 3PL contracts is not appropriate deployment of resources. While the contract 




may not be useful for the supply chain system at that time. In addition, there is a growing 
concern around the output of capacity-building interventions—i.e., whether the results in system 
performance are worth the costs of training and workforce capacity-building efforts. Thus, future 
efforts should be focused on demonstrating immediate impact of capacity building through 
visible change in performance improvement. In addition, utilizing strategies that may be less 
expensive like direct mentoring, on the job training and supportive supervision will be useful. An 
important skill needed by many health workers is behavior change communication and task 
management. This skill will enable them to improve their attitude to work and relationship with 
clients. Building the capacity of staff on contract management and protocols to demand 
accountability from the private sector are important skills for government staff and implementing 
partners who are part of the governance structure for the public-private partners and other 
engagements with 3PLs. 
Recommendation #3.2. Government and donors should develop an active performance 
management strategy to promote effective utilization of deployed resources for supply 
chain implementation.  
 
The use of active performance management strategy is necessary to support 
implementation of supply chain management innovations for service delivery. These strategies 
should be used in the management of both human and materials resources available to the 
HIV/AIDS supply chain system. On human resources management, this can be achieved 
through incentivizing performance through rewards and career promotions (Serumaga, Spisak, 
Rosen, Morgan & Eichler, 2014). In addition, deterrents can put in place through issuance of 
performance queries both verbal and written to staff members that are performing below 
expectation. For private sector organizations working in the HIV/AIDS supply chain, as 3PLs, 
the documentation of performance failures and contract enforcement had been successful 
strategies for performance management. I had use these strategies in my experience 




3PLs through periodic open tendering of the services they provide to attract new 3PL will be a 
useful strategy to maintain performance standards (Agrawal et al., 2016). 
Recommendation #3.3. Government should attract more private sector organizations to 
manage fixed government assets (i.e. warehouses) through public-private-partnership. 
 
One strategy to consider is greater engagement with the private sector that can be held 
accountable by government for direct implementation of the major supply chain activities 
(Agrawal et al., 2016). While there had been complains of poor performance by the private 
sector, especially in warehousing and distribution of products, they provide a better alternative 
on resources accountability and efficient delivery of services compared to government institution 
(Agrawal et al., 2016). This is because as a private institution, they can be called upon by the 
government at any time to account for resources given to them and their contract can be 
terminated if they do not demonstrate tangible progress toward performance improvements. In 
addition, private vendors are likely to have greater performance incentives if Nigeria government 
enhances its performance management system and opens the private contracts up to 
competitive bids. The engagement of the private sector for management of government-owned 
warehouse infrastructure can be through public-private partnership (PPP) as a strategy to 
promote proper resource utilization and accountability. The Nigeria federal government already 
has a PPP policy that can be adapted by the state governments to improve supply chain 
performance (FMOH, 2005). The utilization of PPP has the potential to improve the governance 
structure within the SCM as both the public and private partners must establish a formal 
agreement on performance standards over a specified period. The Federal Ministry of Health; 
Food, and Drug Service Department (FMOH/FDS) through the National Product Supply Chain 
Management Programme (NPSCMP) should take the lead in the development of the scope of 
work and implementation the of PPP at the federal level while providing support to states. This 
should be carried out in consultation with appropriate federal government regulatory agency. At 




the Logistics Management Coordinating Units should take the lead on developing state-level 
scope of work for the PPP.  
 
4. Data Management and Use  
The research also identified the use of inaccurate data for quantification and 
procurement decisions as major barrier to the system. This barrier was due to manual and 
laborious process of data generation and transmission structures from the clinics to the state 
and national levels. In addition, poor record keeping practices, inadequate human resources, 
and the lack of user-friendly standardized data capture forms contributes to this overall lack of 
actionable data. For example, some of the health workers do not have the proper forms to 
document product utilization at the clinics. For those that have the forms, completing them is 
often perceived as more work; hence, they are sometimes unwilling to fill it. Furthermore, 
frequent staff attrition makes these challenges worse. Despite these challenges, the public 
health supply chain system in Nigeria is abounding with different types of data to inform 
strategic decisions on effectiveness and efficiency of the system. Unfortunately, only raw data—
rather than aggregated data—are available to the government officials. For example, the LMCU 
receives the raw data on the quantity of HIV/AIDS products delivered to the clinics from the 
implementing partners. However, government needs to know the number of patients who have 
been or could be treated with these products. Also, government officials also need the data to 
inform them on the level of product availability in the clinics (i.e. stock out rate). The deployment 
of technology to support this process will be useful. For example, the use of electronic logistics 
management information system in Tanzania improved data use significantly with increased 
visibility in the system (Mwencha et al., 2017). 
One of the aims of this study was to explore other models of effective supply chain 




review identified two other successful efforts, one in Tanzania and the other in Ethiopia that 
could be helpful to Nigeria. Tanzania invested in an improved logistics system (via the logistics 
management unit) which resulted in improved data visibility and a decrease in health products 
stock out and expiries (Mwencha et al., 2017). Ethiopia used data on the number of patients 
accessing ARVs in addition to logistics data to inform resupply decision, which helped improve 
HIV/AIDS product availability in the clinics (Berhanemeskel, Beedemariam & Fenta, 2016).  
Recommendation 4.1. Governments should require the use of electronic data 
management systems to improve data processing into information for decision-making. 
 
The deployment of technology for electronic management of logistics data will increase 
data use for decision-making and should lead to overall supply system performance. For 
example, the use of mobile technology in logistics data management will eliminate the need for 
paper report transmission to state or national level that improves real-time stock monitoring and 
product availability (Aranda-Jan, Mohutsiwa-Dibe, & Loukanova, 2014). However, the purchase 
of new data systems in and of itself will not ensure better data is collected. The knowledge and 
willingness of the people utilizing the electronic system is essential to achieve desired results. In 
addition, deployment of electronic systems is capital intensive and requires technological and 
infrastructure support services for the users. The good news for the Nigeria HIV/AIDS program 
is that discussions started by the donors in 2017 to deploy electronic system is yielding positive 
results.  
As at May 2018, an electronic logistics data collection platform had been developed 
under the leadership of the federal and state government, with support of donors. The electronic 
platform is undergoing pilot testing and deployment in some clinics in Nigeria. This should 
significantly improve the health supply chain system if the current momentum to roll out the 
system at the state LMCUs is sustained. Efforts are also ongoing to deploy the system at clinics 




place, the government leadership should focus now on national adoption and use of the system. 
This will include encouraging the staff at the clinics to accurately submit data on time for 
decision-making via mentoring and feedback system from the state LMCUs.  
In addition, simplifying the data collection forms to make them more user-friendly and 
putting mechanisms in place for data validation, with the aid of technology, will support to 
improve the quality of data used for decision-making at the national and state levels. Finally, 
senior government leaders should have access to electronic dashboards that includes supply 
chain management data and demand interpretation of performance trends from the data. The 
utility of these electronic dashboards to improve the vaccine supply chain program in Nigeria 
was noted as a success through improved visibility of product availability at the clinics and 
prompt decision-making by senior leaders to address identified barriers (Sarley et al., 2016). 
Access to these electronic dashboards will also provide visibility to the senior government 
officials when there is a decline in supply chain performance. 
 
5. Infrastructure and System Support 
The research highlighted several infrastructure problems that impair the SCM system, 
including inadequate data management infrastructure (computers, internet access), 
warehousing services (forklifts, fire-fighting equipment, shelving racks etc.), storage space at 
clinics, and lack of clinic space for patient counseling and medication dispensing.    
Recommendation #5.1. Government should develop and enforce the maintenance of 
minimum warehousing standards for health products within the supply chain system. 
  
One strategy to address the warehousing infrastructure deficit is the development of 
minimum warehousing standards. This is different from previous recommendations that 




development and enforcement of minimum standards will enable government and other private 
organizations responsible for management of these infrastructures to understand basic 
requirements and ensure that the SCM system operates within acceptable standards. The 
development minimum warehousing standards is under the purview of the Pharmacists Council 
of Nigeria (PCN) that regulates and approves standards for premises used in management of 
pharmaceutical products in Nigeria. In addition, the National Agency for Food and Drug 
Administration and Control (NAFDAC) that enforces the national laws on use of medical 
products and devices should support through regular monitoring to ensure compliance with 
minimum warehousing standards established by PCN. The establishment of minimum standard 
will serve as baseline to support pharmaceutical-grade warehouse management. In addition, the 
public-sector warehouses should continue to aspire towards the International Organization for 
Standardization (ISO) quality management system (i.e. ISO 9001) certifications on infrastructure 
and management for pharmaceutical-grade warehouses in the long-term.     
Recommendation #5.2. The requirement for data management hardware should be 
addressed through the use of existing infrastructure rather than investing in a new 
hardware system.  
 
Delays in timely submission of logistics is often attributed for unavailability of hardware 
for data submission. This challenge can be addressed through the use of android-based mobile 
phones to collect data. The good news is that the existing software platform has a mobile-based 
application. These android devices are readily accessible to most health workers and can 
address the deficit related to lack of computers for data transmission from the clinics and scale-
up in the use of the technology via installation of the software on available android devices 
(Aranda-Jan, Mohutsiwa-Dibe, & Loukanova, 2014). Furthermore, the challenge of internet 
connectivity can be addressed through government partnership with major mobile network 
providers in Nigeria. The partnership will include these mobile network providers offering free 




barrier associated with cost of submitting logistics data to the platform by user and others that 
may want to visit the system to obtain data for decision-making. The donors and private 
organizations supporting the deployment of the new software should facilitate the discussion 
between the government and mobile network providers. 
 
6. Quality Service Delivery  
The HIV/AIDS program is relatively unique compared to other health care SCM systems.  
This is because HIV/AIDS program has frequent changes in treatment guidelines as the result 
of innovations in treatment options. Thus, there needs to be a system to update the HIV/AIDS 
treatment guidelines when innovations are available. However, new guidelines are not always 
conveyed down to the level of clinic staff. Further, the poor documentation of the quality 
problems (e.g. adverse drug reactions for ARVs) and accurate interpretation of these incidents 
are system problems that need to be addressed (Hui, Vaillancourt, Bair, Wong & King, 2016). 
Also, Avong et al. (2015) highlighted the importance of prompt reporting of adverse drug 
reactions in a standardized format for early detection and management of adverse events on 
clients. Even when these problems are reported, the national government does not provide the 
feedback needed to help worker manage these incidents. Further, the national antiretroviral 
therapy task team, constituted to provide national direction on clinical program implementation, 
does not meet as frequently as expected due to paucity of funds. Similarly, the national 
laboratory technical working group that provides direction on utilization of RTKs also does not 
have regular meetings. This lack of regular meetings by these two oversight groups makes it 
difficult for health workers to provide timely feedback to the national government on health 
service delivery challenges. Essentially, there is no monitoring and oversight system to ensure 
that new guidelines are being implemented consistently across clinics. This leads to varying 




Recommendation #6.1. Governments should strengthen electronic dissemination of 
treatment guidelines and monitoring of compliance with established treatment standards 
at the clinics. 
 
Improving the quality of HIV/AIDS service delivery through the supply chain system is 
essential to enhance the patient experience at the clinics. This includes prompt dissemination of 
national treatment guidelines for RTKs and ARVs management to health workers using 
innovative means (e.g. electronic dissemination) by the federal government. In addition, the 
federal and state governments should collate e-mail addresses of the health workers at the 
clinics to disseminate new decisions on HIV/AIDS product use. The Federal Ministry of Health 
through the HIV/AIDS Division should be responsible for implementation of this 
recommendation.  
Furthermore, capacity-building sessions for the health workers through a structured and 
regular meeting of the national antiretroviral task team and national laboratory technical working 
group is also another intervention that will help to improve quality of HIV/AIDS services. These 
meetings should include sessions on monitoring implementation of new guidelines and provide 
feedback to health workers that identified adverse drug reactions or other quality issues with 
health products used in the clinics (Ehrenkranz et al., 2018). However, the structure of the 
current national meeting where clinicians, pharmacists, and laboratory scientists travel from 
many states and clinics to central location is too expensive to finance on regular basis. Hence, 
the federal and state governments should restructure these meetings using online webinars or 
other means of electronic collaborative discussions. In addition, proactive efforts at collecting 
feedback from the patients on product-related challenges in the use antiretroviral medicines will 






7. Policy Improvements 
Recommendation #7.1.  Government should establish minimum remaining shelf-life 
policies for donated health products to minimize expiries. 
 
Some of the improvements identified by the research will require structured policy 
changes before they can be implemented. For example, determining the minimum remaining 
shelf life of products before they are imported into Nigeria is a policy decision. While most of the 
donor agencies have their own minimum shelf life requirements (typically, requiring that the 
product have a minimum of 75% of its remaining shelf life to be shipped into the country), there 
is no nationally adopted minimum standard in the 2016 national supply chain policy. The 
national regulatory agency (NAFDAC) stipulates a minimum of six months for commercially 
imported products but this may not apply to public health programs. Most of the products used 
in the public health program spend between 8 and 15 months in the country before use. Thus, 
products that are shipped into the country with a six-month shelf life may not end up not being 
used before the product shelf-life expires which becomes a waste management challenge for 
the SCM system. Also, the general health commodities donation guidelines stipulate 50% shelf 
life for donations in emergency (as there is an expectation that in emergencies, most of the 
products will be used immediately). However, there is no specification for normal service 
delivery in the health supply chain policy. Hence, specifying minimum required product shelf life-
-both in percentage and months—would help ensure that products can be used before expiring. 
Recommendation #7.2. The Ministry of Health should ensure that there is specification 
on the level of Government funding in support of health supply chain system. 
 
Another policy improvement is definition of the role of government in funding the public 
health supply chain system in Nigeria. Donor organizations have had to step in to support the 
HIV/AIDS supply chain system because of the limited commitment from the government to 




it is silent on sources of these funds. Further, current policy does not spell out the level of 
government funding needed to support different components of the HIV/AIDS supply chain 
system. This gap will continue to impede sustained system performance and limit the ability of 
the government team in the HIV/AIDS supply chain system to implement required changes 
without external funding support. 
Recommendation #7.3. Government should ensure that the next revision of the national 
health supply chain policy include an implementation plan. 
 
The lack of an adequately financed monitoring strategy for policy implementation was 
another major gap in the current policy framework. While the existing policy framework—the 
“Nigeria Supply Chain Policy for Pharmaceuticals and Other Healthcare Products” (2016) 
contains a description of the tactical roles of the various stakeholders (federal and state 
governments, and clinics) in involved in the SCM system, the lack of a concrete implementation 
plan made it difficult to ensure proper implementation of the current SCM system.   
The Nigeria Federal Ministry of Health, Food and Drug Service Department, should be 
reviewing the existing supply chain policies in 2019.  When revised, the new governmental 
policy statement should include an accompanying implementation plan with the needed funding 
to support implementation and monitoring. The revised Supply Chain Policy for Pharmaceuticals 
and Other Healthcare Products should include an accompanying implementation plan to ensure 
that the underlying policies are successfully implemented. The implementation plan should 
identify the governmental agency responsible for implementing different policy provisions, 
funding sources and levels needed to policy implementation, and a monitoring and reporting 
structure to oversee policy implementation. Finally, the implementation plan should include 
issuance of government circulars to all stakeholders to reinforce the policy provision. The 




need to comply with the government directive on new changes within the public health supply 
chain. 
   
Prioritization of Recommendations 
 
I am mindful that not all recommendations can be implemented at once, as some of 
them will require significant changes in the current policies and practices. Hence, I will be 
sequencing the recommendations into short-term, medium-term, and long-term 
recommendations. These will enable me focus appropriately on the plan for change and guide 
prioritization of efforts to support implementation. This is also important as some of the 
recommendations may be considered as low hanging fruits that will be acceptable to the 
Government leaders and relevant stakeholders for easy implementation while other will require 
significant resource investment. More so, some of the recommendations are precursors needed 
to implement some of the other medium and longer-term recommendations. Thus, these 
recommendations should be implemented first to build the foundation to implement other 
recommendations in the future.  
 
Short-term Recommendations: The following recommendations are considered short-term 
recommendations for implementation in the next 6 to 12 months. In putting together these short-
term recommendations, I am mindful of efforts already ongoing in electronic supply chain data 
management within the national health supply chain system that need to be supported through 
active government leadership. In addition, these recommendations will require minimal financial 
resources, and limited changes to existing policy and protocols supporting the HIV/AIDS supply 
chain system. Finally, these will require limited advocacy to the mid-level managers in the 




 Recommendation #6.1. Government should strengthen electronic dissemination of 
treatment guidelines and monitoring of compliance with established treatment standards 
at the clinics. 
 Recommendation 4.1. Government should require use of electronic data management 
systems to improve data processing into information for decision-making. 
 Recommendation #5.2. The requirement for data management hardware should be 
addressed through the use of existing infrastructure rather than investing in a new 
hardware system.  
 
Medium-term Recommendations: The medium-term recommendations will require about 12 to 
24 months for implementation. These recommendations will require development and issuance 
of government circulars from senior government leaders with some level of changes in the 
current structures and protocols for the public health supply chain program in Nigeria. In 
addition, it will require significant of level advocacy to senior government leaders to facilitate 
implementation of these recommendations. These include: 
 Recommendation #1.2. Government officials should facilitate prompt dissemination of 
changes in the national HIV/AIDS treatment guidelines and SCM system using 
appropriate circulars via electronic systems. 
 Recommendation #1.1. Donors and private sector organizations should engage directly 
with federal and state governments to support coordination and collaboration among the 
different stakeholders in the system to harmonize commodity procurement plans.   
 Recommendation #2.2. Government should disburse budgeted governmental funding for 




 Recommendation #3.2. Government and donors should develop an active performance 
management strategy to promote effective utilization of deployed resources for supply 
chain implementation.  
 Recommendation #2.3. The government should strengthen accountability and 
management structures for the HIV/AIDS SCM system. 
 Recommendation #5.1. Government should develop and enforce the maintenance of 
minimum warehousing standards for health products within the supply chain system.  
 Recommendation #7.1. Government should establish minimum remaining shelf-life 
policies for donated health products to minimize expiries. 
 
Long-term Recommendations: These recommendations will require significant changes in 
government policy and procedures hence will need about 24 to 48 months for implementation. 
Some of the recommendation will require new legislation; other recommendations will take the 
involvement of more private sector payers. These recommendations include: 
 Recommendation #3.1. Government and private sector organizations should develop a 
targeted workforce development strategy to improve supply chain performance. 
 Recommendation #3.3. Government should attract more private sector organizations to 
manage fixed government assets (i.e. warehouses) through public-private-partnership. 
 Recommendation #7.3. Government should ensure that the next revision of the national 
health supply chain policy include an implementation plan. 
 Recommendation #7.2. The Ministry of Health should ensure that there is specification 




 Recommendation #2.1. Government should budget adequate funds to provide 




The survey response rate was 32%, which was lower than the targeted response rate of 
50%. While I used gatekeepers to encourage responses from potential respondents and sent 
periodic reminders, the response rate still fell short of expectations. This may be because the 
clinic and state level staff were not familiar with the name of researcher and there was no 
incentive to participate. For the key informant interviews, many of the potential respondents 
agreed to participate in the interview. My professional networking with most of the respondents 
may have influenced their acceptance to take part in the interviews. However, I explained that 
the interview was an academic research, their participation was voluntary, and they were free to 
decline participation without any consequence. Also, I did not follow up with potential 
respondents after a second e-mail reminder to minimize undue pressure to take part in the 
interview. For those that participated in the interview, I did not interject during their explanations 
and minimized eye contacts to minimize any inadvertent influence on their views via social 
desirability bias.  
Furthermore, my long-term involvement in the Nigeria HIV/AIDS supply chain system for 
the last ten years guided my interpretation of the research findings.  However, I used a second 
coder in analysis of findings to minimize potential researcher bias. In addition, I tried as much as 
possible to stay on message in line with what the respondents proposed without allowing by 
personal bias influence the result analysis and presentation. Furthermore, inputs of the Local 
Government Area (LGA) officials, that is the third tier of government in Nigeria, were not 




collection--their inputs will be useful in future studies. Finally, the study did not cover health 
supply chain integration with other public health supply chain systems in Nigeria (e.g. malaria 





CHAPTER 6: PLAN FOR CHANGE 
 
Implementation of these recommendations will need strategic collaboration with donors, 
implementing partners and senior government leaders involved in the public health supply chain 
system in Nigeria. In my current role as the Deputy Country Director, Supply Chain Operations 
for the USAID Global Health Supply Chain Program – Procurement and Supply Management 
project in Nigeria, I can facilitate some of these dialogues to initiate the process of change. I will 
adopt the Kotter’s eight steps model of leading change (Figure 4) in the implementation of the 
research findings (Kotter, 2007), which I believe will help lead to meaningful improvements. 
Incidentally, I have been actively involved in some of the major changes that had resulted in the 
improvements recorded in the HIV/AIDS supply chain system in Nigeria in the last ten years. 
This will be enable me draw from both my network with relevant stakeholders and knowledge of 
the system to push these changes forward. Implementing Kotter’s eight steps model will involve 
taking the steps to ensure that these recommendations do not go the way of earlier research in 
the public health supply chain space in Nigeria.   
To ensure successful implementation of the recommendations, I will initially focus on the 
short-term recommendations as I noted in Chapter 5. These recommendations have higher 
chances of immediate success with minimal disruption to the existing system. However, if 
implemented, these recommendations will add significant value to the system. First, I will focus 
on electronic data management system that will improve prompt generation of information for 
decision-making via a central data repository. This recommendation leverages the ongoing 
efforts to implement an electronic logistics data management system but adds a 




government officials. Below is the sequential pathway I intend to follow as recommended by 
Kotter: 
Figure 28: Kotter Change Model  
 
(Kotter, 2007) 
1. Create Sense of Urgency:  The first step in the Kotter model is to create a sense of 
urgency about the need for change.  I will achieve this through dissemination of a 
summarized version of my research findings to some of the research respondents, with 
focus on government leaders, who had already shown interest in the results. 
Specifically, I will focus my initial discussion with government officials on the need for 
timely generation data needed for decision-making. This will form the first part of my plan 
for change. Sharing the information with government leaders will create the opportunity 
for internal dialogue. The dialogue will revolve around the kind of information each cadre 
of government official will want to see, the frequency and format of presentation to guide 
decision-making. The focus of the dialogue with government officials will be on their 
thoughts regarding the findings as well as suggestions for how to modify the original 




disseminate the result through a community of practice of public health supply chain 
experts that I belong to in Nigeria, the International Association of Public Health 
Logisticians (IAPHL). This community of practice includes senior government officials, 
donors, private sector players, and implementing partners supporting public health 
supply chain programs in Nigeria. I will try to create the sense of urgency through 
emphasizing that improved data via a harmonized in-country SCM data system, would 
increase the number of patients who could be benefit from the program and clinics that 
could be provided with necessary HIV/AIDS products, both with the same level of 
funding in the country. Furthermore, I intend to publish the research finding in reputable 
public health journals to enable it gain wider visibility and create the required pressure 
for the government leaders to act. This will include highlighting the gaps in the health 
supply chain policy document and, after consulting with government officials, proposing 
revisions to address them.  
2. Build a Guiding Coalition: The IAPHL Nigeria chapter holds its meeting once a month 
in the country. These meetings have an audience from across the states in Nigeria, 
many of whom join online. In addition, some government leaders attend in person. 
Through this forum, I will build a coalition of interested health workers that will be willing 
to share these ideas at their worksites or other areas of influence. To stimulate this 
interest, I intend to request time to make presentations at these meetings to identify the 
gaps in the systems, recommend improvements, and build momentum for change with 
focus on data for decision-making. The leadership team of the HIV/AIDS public health 
supply chain in Nigeria takes part in this forum. I intend to use the opportunity of the 
presentation to stimulate further follow up sessions with the Ministry of Health before the 
presentation. 
3. Form a Strategic Vision and Initiative: Based on the finding from the research, the 




because the government was not at the forefront of leading these initiatives. Instead, 
most of these initiatives were led by donor organizations.  Further, some of the prior 
recommendations did not have accountability structures to monitor implementation. 
Hence, I intend to hold a strategic brainstorming session internally with the government 
health supply chain leadership team on how they want health supply chain data to be 
presented to inform their decisions. This will focus on the use of proper and ‘politically 
acceptable’ strategies in increasing the effectiveness and efficiency of the HIV/AIDS 
supply chain via data visualization techniques with aid of technology. The sessions will 
also include opportunities for the leadership to help modify the research 
recommendations based on their knowledge of the system with the aim on developing 
an implementable strategy on supply chain data management and use for decision-
making. The internal dialogue will be an opportunity to communicate the vision in more 
detail for their buy-in and suggestions. A focal point of discussion will include strategies 
to obtain government commitment in area of funding allocation and disbursement for 
implementation of public health supply chain in Nigeria. However, the initial focus will be 
on how to continuously generate supply chain data that will inform the long-term 
recommendation on funding. Also, I will try to focus on strategies to improve 
accountability and feedback, through supply chain data visualization, to the senior 
leadership about the deliverables achieved through governmental funding. 
4. Enlist Volunteer Army and Communicate the Vision: I will suggest that the 
government leadership team seek interested volunteers within Government agencies 
that will lead the implementation process (as champions) in consultation with donors, 
private sector organizations, and implementing partners. The volunteers will be identified 
through the IAPHL forum and/or National procurement and supply management 
technical working group meetings. Representatives of government officials from the 




the logistics management and coordinating unit (LMCU) and/or IAPHL. The volunteers 
will be individuals who are passionate about meaningful change that will improve the 
lives of patients accessing HIV/AIDS services. I will communicate the vision to these 
volunteers with support of the government leadership that are part of the guiding 
coalition. The communication will be through e-mail listserv set up for that purpose with 
which I will share relevant new supply chain information and receive feedback on 
implementation. The volunteers will be encouraged to conduct peer review on progress 
made at different levels of implementation and seek support from government leaders in 
the guiding collation when needed.    
5. Enable Action By Removing Barriers: It is important to identify key players who may 
oppose or impede changes especially on deployment of technology to support supply 
chain data management. Stakeholder analysis will be used to identify the key 
stakeholders, their interests, and potential opposition to the proposed public health 
supply chain improvements. In addition, proper messaging will be crafted to minimize 
potential opposition to the proposed improvements. This will include the benefits of the 
improvements to the public health system and to the patients accessing health services 
from the clinics. I will also advocate for the issuance of government circulars at the state 
level on the implementation of ideas adopted by the senior leaders. The circulars will 
give the government the needed credit and show they are in the lead in the 
implementation of the new recommendations. Scanned copies of the circulars can be 
disseminated via e-mails to all relevant stakeholders for implementation new changes. 
This will assist to provide conducive environment for implementation of the new ideas. 
Table 7 contains stakeholder analysis on electronic management of HIV/AIDS supply 
chain data in Nigeria.    
Government officials at the federal and state ministries of health and local 




data management system. This is because the electronic data management system will 
provide needed information on the utilization of HIV/AIDS products at the clinics. The 
improved visibility will promote accountability on the use of government and donor 
resources to provide HIV/AIDS services. The government officials have the authority to 
demand clinic workers to submit data electronically and will exercise that power via 
circulars to promote implementation on the new system. The donors and NGOs working 
in the HIV/AIDS program are also very likely to be proponents. This will be a strategy to 
monitor resources deployed and demonstrate accountability to the relevant authorities in 
their host countries. The donor’s involvement may be moderate, as they will expect the 
NGOs to be at the forefront promoting deployment of the system while bringing the 
donors into the conversation if there are challenges. The opponents of the electronic 
data management system will include clinic workers and patients. For the clinic workers, 
they may feel pressured to use their personal android devices to submit data, which may 
be at a personal cost on internet connectivity. However, they will be encouraged to 
submit electronic data explaining how it will reduce their workload. Also, performance-
based incentives (annual recognition certificates and performance bonus) on the number 
of accurate reports submitted on time could be instituted to encourage their participation. 
In addition, the software provider should centrally cover the cost of internet connectivity 
to encourage data submission at no cost to the sender. If these fail, the local 
governments will be requested to deploy staff to manually collect data from the clinics 
and transmit these data electronically. The patients may be other opponents of the 
system as result of concerns on breach in patient confidentiality. However, they will be 
assured the system will only collect data on HIV/AIDS product use and demand pattern 
without any patient identifier. This will minimize the risk of product unavailability when 
they come to the clinics for services. Finally, the private sector distribution providers may 




infrastructure for it. However, the will be persuaded with explanation on how the 




Table 7: Stakeholders Analysis      
Stakeholders Reason Power Resources Likelihood of 
involvement 
Ways to influence 
stakeholders position 




Increase data visibility will 
improve accountability on 
government and donor 
resources and increase 
visibility on service delivery 
High Has authority to demand 
data visibility from clinics 
under Federal 
Management and can 
make policy changes to 






Increase data visibility will 
improve accountability to 
Federal Government and 
Donors to attract more 
support to the state 
through increased product 
supplies  
High Has the authority to 
demand data from clinics 
under State management 
and can make policy 








Increase data visibility will 
guide staff deployment for 
data collection and 
management 
Moderate Can deploy staff to collect 
and transmit data at local 
levels  




service delivery data 





Plan for AIDS 
Relief 
Data visibility will aid 
accountability on funding 
allocated for service 
delivery to justify 
investment to the U.S. 
Congress 
High Will fund the development 
of software system and 
support roll out of the 
system across clinics and 
creation of dashboards 
Moderate Demonstrate benefit 








Data visibility will aid 
accountability on funding 
allocated for service 
delivery to justify 
investment to the Board 
Moderate Will fund the development 
of software system and 
support roll out of the 
system across clinics and 
creation of dashboards 
Moderate Demonstrate benefit 







management will aid 
commodity supply 
decisions to minimize 
waste and justify funding 
Moderate Will support the 
implementation of new 
electronic data 
management system and 
facilitate government use 
of the system 
High  
Opponents of electronic management of HIV/AIDS supply chain data 
Clinic health 
workers 
Will be pressurized to 
submit data timely and 
possibly be required to use 
their own personal android 
devices for data 
submission 
High Staff may decide not to 
use the electronic system 
and continue with manual 
method of data 
processing claiming lack 
of capacity  
High Showcase potential 
reduction in data 
processing errors and 
timely resupply of full 





Concerns on breach in 
confidentiality of patient 
identity if electronic system 
is hacked 
Moderate Can use public media to 
blackmail the 
Government that they are 
planning to breach patient 
confidentiality via 
electronic system 
Moderate Clarify that only 
product information 
will be collated and 





management of distribution 
practices will expose 
inefficiencies in product 
delivery 
Low Responsible for the 
deployment of android 
devices for parts of 
supply chain system. 









6. Generate Short-term Wins: The government-facilitated technical working group 
meetings and the monthly IAPHL meetings will be platforms to celebrate short-term 
successes achieved at each milestone. These will include the adoption of new and 
improved implementation strategies by the government gatekeepers, identification of 
volunteers, identification of barriers to implementation, issuance of implementation 
circulars and any success achieved in securing appointments with senior government 
leaders to present the new ideas. This will sustain the momentum, encourage the 
volunteers, and provide a platform to monitor implementation progress. 
7. Sustain Acceleration: The opportunities that will be provided by the celebration of 
short-wins will also be utilized to sustain momentum for volunteers driving 
implementation of the recommendations. The meetings of the volunteers will be 
scheduled after the IAPHL meetings and via e-mail communications to minimize cost 
implication of participation. A nominee, among the volunteers, who will serve as a 
champion to navigate the government bureaucracies, will lead the volunteer’s meetings. 
However, a volunteer who will be subject matter expert on topic of discussion at each 
meeting will lead different meetings. In addition, feedback will be sought from other 
members of the community of practice on how to surmount implementation barriers. This 
will enable the team to mobilize more volunteers that will sustain the momentum and 
report on progress. In addition, defining the measure of success and establishing key 
performance measures will be used to keep the team engaged. This will enable the team 
to identify small improvements and celebrate successes.    
8. Institute Change: Once breakthroughs are achieved in the government system --
especially in the leadership, allocation, and disbursement of funding to implement public 
health supply chain activities--the changes will be instituted through continuous 
accountability of resources released by the government. The team will be encouraged to 




addition, the LMCU will be used as the government institution to coordinate and report 
on progress by the states. At the national level, FMOH/FDS will be asked to report 
progress on key milestones during the national procurement and supply management 
technical working group meetings and publish these achievements in government 
journals.  
 
Public Health Benefit 
 
HIV/AIDS is a chronic disease that can only be controlled through lifelong antiretroviral 
drugs treatment; much like hypertension must be controlled with regular and reliable 
pharmaceutical treatment and behavior change. Thus, this research identified barriers and 
solutions for an effective and efficient HIV/AIDS supply chain in Nigeria for lifelong treatment of 
people living with the human immunodeficiency virus. While there are significant strides in the 
last decade to improve the system, strengthening coordination at the various levels of 
governments will minimize duplication of efforts in HIV/AIDS commodities procurement and use. 
This will increase the number of clients that can benefit from HIV services.  Increasing the 
availability of RTK tests will help more people know their HIV status through routine screening 
tests and expanding access to ARVs will help more people stay in treatment and reduce their 
viral load. Furthermore, increasing government leadership and accountability through 
performance management will promote access to quality HIV services at the clinics. Prompt 
dissemination of HIV/AIDS treatment guidelines that support the appropriate product selection, 
procurement, and service delivery will ensure that clients benefit from high quality services 
when they visit the clinics.  
Finally, Nigeria is undertaking National AIDS Indicator and Impact Survey that started in 
June 2018 with planned completed in early 2019. This survey will provide information on 




services. This scale-up will be dependent on an effective and efficient HIV/AIDS supply chain to 
ensure that areas with higher prevalence receive needed products for service delivery. The 
planned review of the national supply chain policy in 2019 further opens the window to advocate 
for the inclusion of this research findings into the national supply chain policy.  
 
Conclusion 
The HIV/AIDS supply chain system in Nigeria has made significant improvements in the 
last decade. However, there are still opportunities for improvement to make the system more 
effective and efficient in supporting HIV/AIDS service delivery. These improvements will include 
strengthening coordination across national and state levels in Nigeria, and across public and 
private funders to maximize the use of available resources for procurement and supply 
management. In addition, improving data quality and use for decision-making by the senior 
government officials is essential to inform budgetary allocations and disbursements for supply 
chain implementation. Effective government leadership through performance management and 
greater accountability of the resources deployed in support of HIV/AIDS supply chain is 
essential to support scale of services in Nigeria. Finally, policy revisions that will define the role 
of government in funding HIV/AIDS supply chain in Nigeria and stipulations of remaining shelf 
life of HIV/AIDS products for importation into Nigeria will further strengthen the supply chain 










APPENDIX 1: DEFINITION OF TERMS 
 
Standard Operating Procedures (SOP): these refer to written documentation on how the SCM 
system should operate. The documentation details steps for activity performance which align 
with program goals. In addition, SOPs contains system performance management protocols and 
quality improvement strategies. It also defines the processes to make needed modifications to 
the SCM system. These are part of the procedures to maintain optimal performance while using 
available resources efficiently.   
Logistics: The cycle of operational activities and functions in and among organizations, such as 
procurement, storage and distribution. 
Logistics management: The part of supply chain management that plans, implements, and 
controls the efficient, effective forward and reverses flow and storage of goods, services and 
related information between the point of origin and the point of consumption in order to meet 
customers’ requirement. Logistics management is an integrating function, which coordinates 
and optimizes all logistics activities, as well as integrates logistics activities with other functions 
including marketing, sales manufacturing, finance, and information technology.” (CSCMP, 2011) 
  
Supply chain: A network of organizations engaged in a transactional or long-term relationship 
that as a total output ensures product availability for the end consumer.  
Supply chain management (SCM): “planning and management processes and procedures to 
ensure that products are continuously made available from the manufacturers to the end users 
that need the products” (CSCMP, 2011). 
Pharmaceutical SCM: this is SCM for pharmaceuticals and other health products needed by 
service providers and clients for health service delivery. The other health products include 
diagnostic reagents and consumables for health service delivery. 
Integrated pharmaceutical SCM: A system that is fully developed with clear linkages among 
people, processes and systems. The SCM actors also have a common goal of establishing an 
effective and efficient system through collaborative leadership, management and financing.  
Inventory management: appropriate handling of health products that have been procured 
through standard warehousing and distribution protocols to ensure they get to end users 
maintaining in a timely manner to ensure their full potency. 
Logistics management information system: the processes for data collection, collation, 





APPENDIX 2: SURVEY QUESTIONNAIRES (ANTIRETROVIRAL DRUGS) 
 
Exploring structural and systemic improvements for effective and efficient 
pharmaceutical supply chain management for HIV/AIDS in Nigeria 
Survey Questionnaires 
Survey Instrument Number……………………………. 
Introduction 
Please take 30 minutes to complete this survey 
This survey is being conducted as part of the Doctor of Public Health (DrPH) degree dissertation in the 
University of North Carolina at Chapel Hill, NC USA. The survey is focused on exploring the structural and 
systemic improvements for an effective and efficient public-sector pharmaceutical supply chain system 
(SCM) for HIV/AIDS service delivery in Nigeria, with a focus on the ‘Six Rights’ of a logistics system. These 
‘Six Rights’ refers to the right product being available in the right quantity, and in the right condition, at 
the right place, in the right time and at the right cost. The HIV/AIDS products referred to in this survey 
are antiretroviral drugs (ARVs). The survey will seek for your opinion on HIV/AIDS pharmaceutical 
supply chain management improvements. Improvements may also include adoptions of external models 
from elsewhere and/or process improvements within the current system to promote effectiveness and 
efficiency of the pharmaceutical system for HIV/AIDS system in Nigeria. Your opinions are confidential 
and cannot to be linked to you. All responses are anonymous; hence respondents cannot be identified 
as the questionnaire will be tagged with serial number in the space provided above. You may submit the 
completed survey electronically via qualtrics or e-mail or return it in hard copy in a sealed envelope for 
confidentiality. For questions please contact; Innocent Ibegbunam innoibe@live.unc.edu Phone +234-
803-5030-619 or Prof Pam Silberman, pam_silberman@unc.edu 
 
Instructions 
i. Please select an option(s) to indicate your opinion to the statement under each section. 
ii. Provide text in the box to give other thoughts on barriers to or potential solutions to specific 
pharmaceutical SCM best practices as noted in the question.  
iii. You may also use additional attachments if the provided space is not sufficient to address your 
point.  
iv. Kindly share any available material(s) or references to further support your opinion. 
A. Background  
This section covers background information on your experience, role and organization as part of the 
pharmaceutical supply chain management for HIV/AIDS program in Nigeria.  
1. How long have you worked within the HIV/AIDS pharmaceutical supply chain management (SCM) 




a. Less than 3 years………. 
b. 3-6 years……. 
c. 7-10 years……. 
d. More than 10 years………             
2. At what level(s) of the pharmaceutical SCM space have you worked? (Select all that may apply).  
a. Health facility…… 




f. Others, please specify……………….  
3. In which part of Nigeria are you working currently on HIV/AIDS pharmaceutical SCM? (Select)  
a. Northern Nigeria 
b. Southern Nigeria 
c. Federal Capital Territory (FCT) 
4. Which of the following type of organization is your main employer currently? (Select the entity).  
a. Government… 
b. Non-Governmental Organization…. 
c. Donor agencies… 
d. Private sector… 
e. Others, please specify………………    
5. What is your current role in the pharmaceutical supply chain with your organization? (Select all that 
apply) 
a. Serving clients…… 
b. Product selection……… 
c. Quantification & Procurement………. 
d. Warehousing and Distribution……… 
e. Logistics Management Information System………. 




g. Others, please specify……………………………….       
B. Product Selection 
Product selection is the process of choosing the name, strength, formulation, pack size and other 
characteristics of HIV/AIDS product(s) required for service delivery. The products are used to meet 
specific health needs of the target population in an identified location. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for antiretroviral drugs in Nigeria today on product 
selection? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers  1 2 3 4 5 0 
1 New ARVs are not included in the 
national standard treatment guidelines 
      
2  National standard treatment guidelines 
for ARVs are not distributed to health 
workers 
      
3 Poor reporting of adverse drug reactions 
to new ARVs to the National Regulatory 
Authority 
      
4 Lack of funding to procure new ARVs       
5 Cost to procure new ARVs       
6 Others (please add below)       
7        
8        
9        
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on product selection? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Annual revision of the national standard 
treatment guidelines (STG) on ARVs 
      
2 Prompt dissemination of STG on ARVs to 
health workers across the country 
      
3 Prompt reporting of adverse drug 
reaction on ARVs to national regulatory 





4 Increased funding from Government at 
all Levels to support procurement of 
new ARVs 
      
5 Decreased cost of new ARVs by 
manufacturer 
      
6 Others (please add below)       
7        
8        
9        
 
C. Quantification and Procurement 
Quantification: Is an ongoing process of estimating the HIV/AIDS product quantities and funding needs 
of a program over an identified period in the future to ensure uninterrupted supply of products to the 
health service providers and clients. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on quantification? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers  1 2 3 4 5 0 
1 Inaccurate ARVs SCM data used for 
quantification 
      
2 Limited human resource capability in 
Nigeria to conduct ARVs quantification 
exercise 
      
3 ARVs quantification information not 
provided in a timely manner to help with 
Government procurement decisions 
      
4 ARVs quantification information not 
provided in a timely manner to help with 
Donors procurement decisions 
      
5 Inadequate funding to purchase ARVs 
needs identified during quantification 
      
6 Limited use of ARVs quantification result 
to inform procurement within 
Government system 
      
7 Others (please add below)       
8        









How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on quantification? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Provision of accurate ARVs SCM data for 
quantification exercise 
      
2 Training of Nigerians on ARVs 
quantification processes and tools 
      
3 Prompt dissemination of ARVs 
quantification results within a defined 
period to the Government 
      
4 Prompt dissemination of ARVs 
quantification results within a defined 
period to the Donors 
      
5 Prompt mobilization of funds required 
to procure ARVs from the result of 
quantification exercise 
      
6 Use of ARVs quantification results to 
inform procurement within Government 
system 
      
7 Use of ARVs quantification results to 
inform procurement within Donor 
agencies 
      
8 Others (please add below)       
9        
 
 
D. Warehousing and distribution 
Warehousing & Distribution: the processes of receiving, storing and managing the HIV/AIDS products 
that have been procured under appropriate conditions and transporting the product, under appropriate 




How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on warehousing and 
distribution? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers 1 2 3 4 5 0 
1 Inadequate pharmaceutical-grade 
warehouses for ARVs 
      
2 Delays in pick-and-pack (packaging and 
labeling of products for each clinic) of 
ARVs at the warehouses 
      
3 Failure to follow the first-to-expire first-
out guidelines in managing ARVs 
      
4 Late delivery of ARVs to clinics       
5 Poor vehicular access road to clinics       
6 Others (please add below)       
7        
8        
9        
 
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for ARVs in Nigeria on warehousing and 
distribution? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Increase in number and sizes of 
pharmaceutical-grade warehouses for 
managing ARVs 
      
2 Automation of warehouse management 
system for pick-and-pack of ARVs 
      
3 Implementation of the first-to-expire 
first-out guidelines 
      
4 Engagement of more private sector 
delivery agents 
      
5 Use of different vehicle types to access 
remote clinics 
      




7        
8        
9        
 
E. Serving clients 
Serving clients refers to the processes of health service delivery by the health worker(s) to the clients at 
the service delivery points using HIV/AIDS products. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on serving clients? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers 1 2 3 4 5 0 
1 Unavailability of ARVs in the clinics       
2 Limited human resources for ARVs 
dispensing in clinics 
      
3 Non-adherence to ARVs national 
standard treatment guidelines 
      
4 Increasing expiries of ARVs at clinics        
5 Limited storage space at clinics for ARVs       
6 Others (please add below)       
7        
8        
9        
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on serving clients? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solution 1 2 3 4 5 0 
1 Increased quantity of ARVs supplied to 
clinics at single delivery 
      
2  Training and task-shifting to increase 
number of health workers that can 
manage ARVs in clinics 
      
3 Increased adherence to ARVs standard 
treatment guidelines 
      




guideline in dispensing ARVs 
5 Refurbishment of ARVs storage space at 
clinics 
      
6 Others (please add below)       
7        
8        
9        
 
 
F. Logistics management information system (LMIS) 
LMIS refers to systems and process for collecting, collating, submitting and using logistic data from the 
clinics to a higher level in the system for decision-making. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on LMIS? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers 1 2 3 4 5 0 
1 Poor SCM record keeping practices on 
ARVs consumption 
      
2 Unavailability of SCM tools for ARVs 
record keeping (e.g. daily consumption 
register, inventory control card) 
      
3 Late submission of ARVs SCM data to 
higher level 
      
4 Inaccurate ARVs SCM data for decision-
making 
      
5 Inadequate infrastructures for ARVs 
SCM data submission (e.g. computer, 
internet) 
      
6 Others (please add below)       
7        
8        
9        
 
 
How important are the following potential solutions to the effective and efficient operation of the 




Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 




Solution  1 2 3 4 5 0 
1 Clinic staff accountability on accurate 
and timely ARVs record keeping 
      
2 Provision of SCM tools for ARVs record 
keeping 
      
3 Timely submission of ARVs SCM data       
4 Use of accurate ARVs SCM data for 
decision-making 
      
5 Provision of infrastructures for ARVs 
SCM data submission (e.g. computer, 
internet) 
      
6 Others (please add below)       
7        
8        
9        
 
G. Leadership and systems support 
Leadership and system support refers to the internal and external support required by the public-sector 
pharmaceutical SCM for from different stakeholders that are working within and outside the system to 
ensure there are no disruptions in the system for an uninterrupted flow of antiretroviral drugs from the 
manufacturers to the clinics. The logistics management coordinating unit (LMCU) at the state level and 
National Product Supply Management Program (NPSCMP) at the national level provide governance 
structures to support public-sector HIV pharmaceutical SCM system. The Procurement and Supply 
Management Technical Working Group (PSM-TWG) meetings serves as coordination forum for the 
NPSCMP and LMCU to engage with donors and implementing organizations at the national and state 
levels respectively on public-sector pharmaceutical SCM. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on leadership and systems 
support? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure. 
Serial 
Number  
Barriers 1 2 3 4 5 0 
1 Unclear scope of work for LMCU       




3 Inadequate funding to support LMCU 
task 
      
4 Inadequate procedures to account for 
ARVs in the public-sector HIV 
pharmaceutical SCM 
      
5 Ineffective procurement and supply 
management technical working group 
(PSM-TWG) meetings 
      
6 Unplanned changes in SCM within a 
short period 
      
7 Others (please add below)       
8        





How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for ARVs in Nigeria today on leadership and 
systems support? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Development of clear scope of work for 
LMCU 
      
2 Development of clear scope of work for 
NPSCMP 
      
3 Provision of funding to support LMCU 
task 
      
4 Establishment of accountability and 
supervisory framework for HIV SCM 
resources 
      
5 Structured and effective PSM TWG 
meetings 
      
6 Development of framework for SCM 
system modifications 
      
7 Others (please add below)       
8        





H. System disruption 
Please answer the following questions. If the spaces provided are not sufficient, please add an 
attachment as needed.                   
1. Consider one incident of pharmaceutical system disruption for antiretroviral drugs supplies 
within the last 12 months (including stock-out) or any other significant disruption to 
effectiveness or efficiency of the system. What was/were one or two of the main causes of this 





2. What is/are one or two of the most important steps you would recommend to prevent the 
disruption of pharmaceutical SCM for antiretroviral drugs in future? Please describe these steps 






























APPENDIX 3: SURVEY QUESTIONNAIRES (HIV RAPID TEST KITS) 
 
Exploring structural and systemic improvements for effective and efficient 
pharmaceutical supply chain management for HIV/AIDS in Nigeria 
Survey Questionnaires 
Survey Instrument Number……………………………. 
Introduction 
Please take 30 minutes to complete this survey 
This survey is being conducted as part of the Doctor of Public Health (DrPH) degree dissertation in the 
University of North Carolina at Chapel Hill, NC USA. The survey is focused on exploring the structural and 
systemic improvements for an effective and efficient public-sector pharmaceutical supply chain system 
(SCM) for HIV/AIDS service delivery in Nigeria, with a focus on the ‘Six Rights’ of a logistics system. These 
‘Six Rights’ refers to the right product being available in the right quantity, and in the right condition, at 
the right place, in the right time and at the right cost. The HIV/AIDS products referred to in this survey 
are HIV Rapid Test kits (RTKs). The survey will seek for your opinion on HIV/AIDS pharmaceutical supply 
chain management improvements. Improvements may also include adoptions of external models from 
elsewhere and/or process improvements within the current system to promote effectiveness and 
efficiency of the pharmaceutical system for HIV/AIDS system in Nigeria. Your opinions are confidential 
and cannot to be linked to you. All responses are anonymous; hence respondents cannot be identified 
as the questionnaire will be tagged with serial number in the space provided above. You may submit the 
completed survey electronically via qualtrics or e-mail or return it in hard copy in a sealed envelope for 
confidentiality. For questions please contact; Innocent Ibegbunam innoibe@live.unc.edu Phone +234-
803-5030-619 or Prof Pam Silberman, pam_silberman@unc.edu 
 
Instructions 
v. Please select an option(s) to indicate your opinion to the statement under each section. 
vi. Provide text in the box to give other thoughts on barriers to or potential solutions to specific 
pharmaceutical SCM best practices as noted in the question.  
vii. You may also use additional attachments if the provided space is not sufficient to address your 
point.  
viii. Kindly share any available material(s) or references to further support your opinion. 
A. Background  
This section covers background information on your experience, role and organization as part of the 
pharmaceutical supply chain management for HIV/AIDS program in Nigeria.  
1. How long have you worked within the HIV/AIDS pharmaceutical supply chain management (SCM) 
sector in Nigeria? (Please select what applies).  




f. 3-6 years……. 
g. 7-10 years……. 
h. More than 10 years………             
2. At what level(s) of the pharmaceutical SCM space have you worked? (Select all that may apply).  
g. Health facility…… 




l. Others, please specify……………….  
3. In which part of Nigeria are you working currently on HIV/AIDS pharmaceutical SCM? (Select)  
I. Northern Nigeria 
J. Southern Nigeria 
K. Federal Capital Territory (FCT) 
4. Which of the following type of organization is your main employer currently? (Select the entity).  
f. Government… 
g. Non-Governmental Organization…. 
h. Donor agencies… 
i. Private sector… 
j. Others, please specify………………    
5. What is your current role in the pharmaceutical supply chain with your organization? (Select all that 
apply) 
h. Serving clients…… 
i. Product selection……… 
j. Quantification & Procurement………. 
k. Warehousing and Distribution……… 
l. Logistics Management Information System………. 
m. Monitoring and Evaluation……….  




B. Product Selection 
Product selection is the process of choosing the name, strength, formulation, pack size and other 
characteristics of HIV/AIDS product(s) required for service delivery. The products are used to meet 
specific health needs of the target population in an identified location. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for HIV Rapid Test kits (RTKs) in Nigeria today on product 
selection? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers  1 2 3 4 5 0 
1 New RTKs are not included in the 
national HIV testing algorithm 
      
2  National HIV Testing algorithm for RTKs 
are not distributed to health workers 
      
3 Poor reporting of failed quality controls 
with new RTKs to the National 
Regulatory Authority 
      
4 Lack of funding to procure new RTKs       
5 Cost to procure new RTKs       
6 Others (please add below)       
7        
8        
9        
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on product selection? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Biennial review of national HIV testing 
algorithm for RTKs 
      
2 Prompt dissemination of RTKs testing 
algorithm to health workers across the 
country 
      
3 Prompt reporting failed quality control 
tests RTKs to national regulatory 
authority 
      




all Levels to support procurement of 
new RTKs 
5 Decreased cost of new RTKs by 
manufacturer 
      
6 Others (please add below)       
7        
8        
9        
 
C. Quantification and Procurement 
Quantification: Is an ongoing process of estimating the HIV/AIDS product quantities and funding needs 
of a program over an identified period in the future to ensure uninterrupted supply of products to the 
health service providers and clients. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on quantification? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers  1 2 3 4 5 0 
1 Inaccurate RTKs SCM data used for 
quantification 
      
2 Limited human resource capability in 
Nigeria to conduct RTKs quantification 
exercise 
      
3 RTKs quantification information not 
provided in a timely manner to help 
with Government procurement 
decisions 
      
4 RTKs quantification information not 
provided in a timely manner to help 
with Donors procurement decisions 
      
5 Inadequate funding to purchase RTKs 
needs identified during quantification 
      
6 Limited use of RTKs quantification result 
to inform procurement within 
Government system 
      
7 Others (please add below)       
8        







How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on quantification? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Provision of accurate RTKs SCM data for 
quantification exercise 
      
2 Training of Nigerians on RTKs 
quantification processes and tools 
      
3 Prompt dissemination of RTKs 
quantification results within a defined 
period to the Government 
      
4 Prompt dissemination of RTKs 
quantification results within a defined 
period to the Donors 
      
5 Prompt mobilization of funds required 
to procure RTKs from the result of 
quantification exercise 
      
6 Use of RTKs quantification results to 
inform procurement within 
Government system 
      
7 Use of RTKs quantification results to 
inform procurement within Donor 
agencies 
      
8 Others (please add below)       
9        
 
D. Warehousing and distribution 
Warehousing & Distribution: the processes of receiving, storing and managing the HIV/AIDS products 
that have been procured under appropriate conditions and transporting the product, under appropriate 
conditions, to service delivery points where they are needed to provide health services to the clients. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on warehousing and 
distribution? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  





1 Inadequate pharmaceutical-grade 
warehouses for RTKs 
      
2 Delays in pick-and-pack (packaging and 
labeling of products for each clinic) of 
RTKs at the warehouses 
      
3 Failure to follow the first-to-expire first-
out guidelines in managing RTKs 
      
4 Late delivery of RTKs to clinics       
5 Poor vehicular access road to clinics       
6 Others (please add below)       
7        
8        
9        
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria on warehousing and 
distribution? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solutions  1 2 3 4 5 0 
1 Increase in number and sizes of 
pharmaceutical-grade warehouses for 
managing RTKs 
      
2 Automation of warehouse management 
system for pick-and-pack of RTKs 
      
3 Implementation of the first-to-expire 
first-out guidelines 
      
4 Engagement of more private sector 
delivery agents 
      
5 Use of different vehicle types to access 
remote clinics 
      
6 Others (please add below)       
7        
8        
9        
 
E. Serving clients 
Serving clients refers to the processes of health service delivery by the health worker(s) to the clients at 




How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on serving clients? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barriers 1 2 3 4 5 0 
1 Unavailability of RTKs in the clinics       
2 Limited human resources for HIV 
screening using RTK in clinics 
      
3 Non-adherence to RTKs national testing 
algorithm 
      
4 Increasing expiries of RTKs at clinics        
5 Limited storage space at clinics for RTKs       
6 Others (please add below)       
7        
8        
9        
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on serving clients? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solution 1 2 3 4 5 0 
1 Increased quantity of RTKs supplied to 
clinics at single delivery 
      
2  Training and task-shifting to increase 
number of health workers that can 
manage RTKs in clinics 
      
3 Increased adherence to RTKs national 
testing algorithm 
      
4 Practicing first-to-expire first-out 
guideline in utilizing RTKs 
      
5 Refurbishment of RTKs storage space at 
clinics 
      
6 Others (please add below)       
7        
8        







F. Logistics Management Information System (LMIS) 
LMIS refers to systems and process for collecting, collating, submitting and using logistic data from the 
clinics to a higher level in the system for decision-making. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on LMIS? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Barrier 1 2 3 4 5 0 
1 Poor SCM record keeping practices on 
RTKs utilization 
      
2 Unavailability of SCM tools for RTKs 
record keeping (e.g. daily utilization 
register, inventory control card) 
      
3 Late submission of RTKs SCM data to 
higher level 
      
4 Inaccurate RTKs SCM data for decision-
making 
      
5 Inadequate infrastructures for RTKs SCM 
data submission (e.g. computer, 
internet) 
      
6 Others (please add below)       
7        
8        
9        
 
 
How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on LMIS? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solution  1 2 3 4 5 0 
1 Clinic staff accountability on accurate 
and timely RTKs record keeping 
      
2 Provision of SCM tools for RTKs record 
keeping 




3 Timely submission of RTKs SCM data       
4 Use of accurate RTKs SCM data for 
decision-making 
      
5 Provision of infrastructures for RTKs 
SCM data submission (e.g. computer, 
internet) 
      
6 Others (please add below)       
7        
8        
9        
 
G. Leadership and systems support 
Leadership and system support refers to the internal and external support required by the public-sector 
pharmaceutical SCM for from different stakeholders that are working within and outside the system to 
ensure there are no disruptions in the system for an uninterrupted flow of HIV rapid test kits from the 
manufacturers to the clinics. The logistics management coordinating unit (LMCU) at the state level and 
National Product Supply Management Program (NPSCMP) at the national level provide governance 
structures to support public-sector HIV pharmaceutical SCM system. The Procurement and Supply 
Management Technical Working Group (PSM-TWG) meetings serves as coordination forum for the 
NPSCMP and LMCU to engage with donors and implementing organizations at the national and state 
levels respectively on public-sector pharmaceutical SCM. 
How important are the following potential barriers to the effective and efficient operation of the current 
public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on leadership and systems 
support? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure. 
Serial 
Number  
Barrier 1 2 3 4 5 0 
1 Unclear scope of work for LMCU       
2 Unclear scope of work for NPSCMP       
3 Inadequate funding to support LMCU 
task 
      
4 Inadequate procedures to account for 
RTKs in the public-sector HIV 
pharmaceutical SCM 
      
5 Ineffective procurement and supply 
management technical working group 
(PSM-TWG) meetings 
      
6 Unplanned changes in SCM within a 
short period 
      




8        




How important are the following potential solutions to the effective and efficient operation of the 
current public-sector HIV pharmaceutical SCM system for RTKs in Nigeria today on leadership and 
systems support? 
Please select “Very important = 5” or “Important = 4” or “Moderately Important = 3” or “Slightly 
Important = 2” or “Not Important = 1” in the Nigeria Pharmaceutical SCM of today. Select “don’t know = 
0” if you are not sure.  
Serial 
Number  
Solution 1 2 3 4 5 0 
1 Development of clear scope of work for 
LMCU 
      
2 Development of clear scope of work for 
NPSCMP 
      
3 Provision of funding to support LMCU 
task 
      
4 Establishment of accountability and 
supervisory framework for HIV SCM 
resources 
      
5 Structured and effective PSM TWG 
meetings 
      
6 Development of framework for SCM 
system modifications 
      
7 Others (please add below)       
8        
9        
 
H. System disruption 
Please answer the following questions. If the spaces provided are not sufficient, please add an 
attachment as needed.                   
3. Consider one incident of pharmaceutical system disruption for HIV rapid test kits supplies 
within the last 12 months (including stock-out) or any other significant disruption to 
effectiveness or efficiency of the system. What was/were one or two of the main causes of this 








4. What is/are one or two of the most important steps you would recommend to prevent the 
disruption of pharmaceutical SCM for HIV rapid test kits in future? Please describe these steps 










































APPENDIX 4: KEY INFORMANT INTERVIEW GUIDE 
 
Key informant interview Questions   
Introduction 
The purpose of this interview is to inform policy recommendations for promoting a sustainable 
pharmaceutical and laboratory supply chain management system for HIV/AIDS service delivery 
in Nigeria as part of a doctoral dissertation. The interview follows a survey I conducted in 
November/December 2017 among some key stakeholders in Nigeria supporting HIV/AIDS 
pharmaceutical and laboratory supply chain management (SCM). In total, I received responses 
from 45 persons in the ARV supply chain, and 21 persons in the RTKs supply chain system.  
The survey was to understand the barriers and solutions for an effective and efficient SCM 
system that covers the six-components of the supply chain system including: product selection, 
quantification, warehousing and distribution, logistics management information system, client 
services, and leadership and systems support. The key informant interview is to identify 
workable solutions to the problems identified by the respondents. I have sent you a summary of 
their responses in advance and hope you had a chance to look at the document before this 
interview. 
The interviews will take about 45 to 60 minutes. The interviews will be confidential and 
information collected through this process will only be used for completion of a doctoral 
dissertation. Your identity will remain completely anonymous and the information you provide 
will not in any way be associated with you. I request your permission to tape-record this 
interview to enable be capture your views accurately.  
Before we proceed, are there any questions that you have about the study, this interview or any 
clarifications? 
Do I have your permission to start recording the interview? 
General overview  
First, I will like to get some information about your role in the Nigeria HIV/AIDS supply chain 
management (SCM) system; 
How long have you worked in the HIV/AIDS pharmaceutical and laboratory SCM in Nigeria and 
what is (was) your role? 
What is your overall assessment of the current pharmaceutical and laboratory SCM for 
HIV/AIDS service delivery in Nigeria? 
Product selection:  In general, respondents for both the ARVs and RTKs supply chain system 
thought that the major barriers were the failure to promptly distribute new testing algorithms or 
treatment guidelines to health workers, and the failure of people at the local level to promptly 
report quality problems (either failed quality controls for RTKs, or adverse drug reactions) to the 
National Regulatory Authority.   
What do you think are the major constraints to improve product selection in HIV/AIDS SCM? To 




What systems could be put in place to address these problems?  (Dissemination of guidelines 
and reporting of quality problems to the authorities, stakeholder’s engagement at the clinics, as 
well as any new issues the respondent raised).   
Quantification and Procurement:  In general, respondents identified problems with inaccurate 
data being used or data not being used to inform procurement within the Government system, 
and that quantification information is not provided in a timely manner to help donors with their 
procurement decisions.     
In your opinion what do you think are the constraints to improve quantification and procurement 
in the HIV/AIDS SCM? To what extent do you think the identified barriers affects information for 
procurement decisions within Government and Donor systems? 
What systems could be put in place to address these problems?  (Inaccurate data being used 
for quantification, information not provided timely for decision making, and any new issues the 
respondent raised).  
Warehousing and Distribution: Most of the respondents identified late delivery of ARVs and 
RTKs to the clinics and expiry of products as major barriers often due to poor vehicular access 
road along with limited pharmaceutical-grade warehouses to manage the supply chain. 
Ineffective communication and lack of real-time monitoring of distribution were also identified as 
barriers. 
What do you think are the constraints to improve warehousing and distribution for HIV/AIDS 
SCM system? To what extent do you think identified barriers affect warehousing and 
distribution?  
What systems could be put in place to address these problems? (Late deliveries, limited 
pharmaceutical-grade warehouse, ineffective communication and any new issues the 
respondent raised).  
Logistics Management Information System (LMIS): The unavailability of logistics tools and 
poor record keeping practices were identified by most of the respondents as barriers to the 
supply chain system. This often results in late submission of reports due to lack infrastructural 
support. 
 What do you think are the major constraints to improve logistics management information 
system for the HIV/AIDS SCM? To what extent do the identified barriers affect LMIS? 
What systems could be put in place to address these problems? (Unavailability of logistics tools, 
poor record keeping practices, late submission of reports due to lack of infrastructural support 
and any new issues the respondent raised).   
Serving the clients: Most of the respondents identified unavailability of both RTKs and ARVs 
as primary barrier to service delivery to clients. This is often due to lack of storage space to 
keep more supplies in the clinics and limited human resources to appropriately document 
utilization.  
In your opinion what do you think are constraints to improve serving clients in HIV/AIDS SCM? 




What systems could be put in place these problems? (unavailability of product, limited storage 
space, limited human resources and any new issues the respondent raised) 
Leadership and System Support: Inadequate funding and limited supervisory and 
accountability framework were identified as barriers under leadership system for the logistics 
management coordinating unit (LMCU). Also identified is frequent and unplanned changes to 
the HIV/AIDS SCM.  
In your opinion what do you think are constraints to improve leadership and system support for 
the HIV/AIDS SCM? To what extent do you think inadequate funding, limited supervisory and 
accountability framework affects leadership and systems support?  
What systems could be put in place to address these problems? (inadequate funding and 
limited supervisory and accountability framework, frequent and unplanned changes to HIV/AIDS 
SCM and any new issues the respondent raised) 
Do you think the current policy and guidelines for HIV/AIDS supply chain management is 
adequate for an effective and efficient supply chain management? If yes, how so? If No, what 
policy changes can be made for an effective and efficient SCM?  
Conclusion 
Considering barriers to the implementation of previous recommendations to improve the 
HIV/AIDS supply chain system, what do you think should be done differently for a sustainable 
implementation of the new recommendations in the short-term, medium-term and long-term?  
Which recommendation should be top priority to improve the system? Please explain.  
What other factor(s) in the environment may be considered essential to improve the overall 
HIV/AIDS supply chain management to ensure uninterrupted availability of needed products for 
service delivery? 
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